+

WO1999061463A1 - Nouvelles proteines secretees et associees a une membrane et leurs utilisations - Google Patents

Nouvelles proteines secretees et associees a une membrane et leurs utilisations Download PDF

Info

Publication number
WO1999061463A1
WO1999061463A1 PCT/US1999/011842 US9911842W WO9961463A1 WO 1999061463 A1 WO1999061463 A1 WO 1999061463A1 US 9911842 W US9911842 W US 9911842W WO 9961463 A1 WO9961463 A1 WO 9961463A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
nucleic acid
stmst
bdsf
Prior art date
Application number
PCT/US1999/011842
Other languages
English (en)
Inventor
Sean A. Mccarthy
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Priority to AU41015/99A priority Critical patent/AU4101599A/en
Priority to CA002328902A priority patent/CA2328902A1/fr
Priority to JP2000550867A priority patent/JP2002516079A/ja
Priority to EP99924537A priority patent/EP1082335A4/fr
Publication of WO1999061463A1 publication Critical patent/WO1999061463A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • Signaling factors play an important role in the development and functioning of different cell types by allowing for communication between interacting cells. Such factors provide a signal between cells which can cause cells which recognize the signal to perform specialized tasks, such as cell growth, differentiation and/or proliferation.
  • cells ofthe immune system characteristically express a variety of signaling proteins which are crucial to proper functioning ofthe immune system.
  • Such proteins include secreted immunoglobulins and non-immunoglobulin molecules which interact with cellular adhesion molecules, as well as other selected target molecules.
  • Many of these proteins are members ofthe immunoglobulin (Ig) superfamily of proteins, characterized by the existence of at least one immunoglobulin (Ig)-like domain.
  • Ig immunoglobulin
  • Such proteins function in a variety of immune cell functions ranging from immune cell development and differentiation, antigen recognition, antibody production, cellular signal transduction, and cellular homing of immune responsive cells from the circulation to sites of increased antigen concentration.
  • GPCRs G protein-coupled receptors
  • GPCRs form one ofthe largest receptor superfamilies found in nature, and it is estimated that greater than 1000 different such receptors exist in mammals.
  • GPCRs Upon binding of extracellular ligands, GPCRs interact with a specific subset of heterotrimeric G-proteins that can then, in their activated forms, inhibit or activate various effector enzymes and/or ion channels.
  • the ligands for many of these receptors are known although there exists an ever-increasing number of GPCRs which have been identified in the sequencing ofthe human genome for which no ligands have yet been identified. This latter subfamily of GPCRs is called the ophan family of GPCRs. In addition to both GPCRs with known ligands, as well as orphan GPCRs, there exist a family of GPCR-like molecules which share significant homology as well as many ofthe structural properties ofthe GPCR superfamily.
  • a family of GPCR-like proteins which arises from three alternatively-spliced forms of a gene occurring between the CD4 and triosephosphate isomerase genes at human chromosome 12pl3, has been recently identified (including protein A-l, A-2, and A-3).
  • Ansari-Lari et al. (1996) Genome Res. 6(4):314-326. Comparative sequence analysis ofthe syntenic region in mouse chromosome 6 has further revealed a murine homologue of at least the A-2 splice product.
  • Ansari-Lari et al (1998) Genome Res. 8(l):29-40.
  • the present invention is based, at least in part, on the discovery of novel secreted proteins and membrane-associated proteins.
  • the present invention invloves novel signaling molecules, referred to herein as Brain-Derived Signaling Factor ("BDSF") molecules, as well as the nucleic acids encoding them.
  • BDSF Brain-Derived Signaling Factor
  • the BDSF molecules ofthe present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding BDSF proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of BDSF-encoding nucleic acids.
  • a BDSF nucleic acid molecule is 60% homologous to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or complements thereof.
  • the isolated nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, or a complement thereof.
  • an isolated nucleic acid molecule has the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or a complement thereof.
  • the nucleic acid molecule further comprises nucleotides 244-701 of SEQ ID NO: 1.
  • the nucleic acid molecule further comprises nucleotides 31 -487 of SEQ ID NO:4
  • a BDSF nucleic acid molecule is 60% homologous to the nucleotide sequence shown in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or a complement thereof.
  • an isolated nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:6, SEQ ID NO: 8, SEQ ID NO:9, or a complement thereof.
  • a BDSF nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5. In another embodiment, a BDSF nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:7 or SEQ ID NO: 10. In a preferred embodiment, a BDSF nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 60% homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:10.
  • an isolated nucleic acid molecule encodes the amino acid sequence of human BDSF.
  • the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:5.
  • an isolated nucleic acid molecule encodes the amino acid sequence of murine BDSF.
  • the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 10.
  • an isolated nucleic acid molecule ofthe present invention encodes a protein, preferably a BDSF protein, which includes an immunoglobulin-like domain.
  • an isolated nucleic acid molecule ofthe present invention encodes a protein, preferably a BDSF protein, which includes a signal sequence, an immunoglobulin-like domain, and, preferably, is secreted.
  • a BDSF nucleic acid molecule encodes a BDSF protein and is a naturally occurring nucleotide sequence.
  • nucleic acid molecules preferably BDSF nucleic acid molecules, which specifically detect BDSF nucleic acid molecules relative to nucleic acid molecules encoding non-BDSF proteins.
  • a nucleic acid molecule is at least 450, preferably 500-700, more preferably 700-900, more preferably 900-1100, and even more preferably 1100-1120 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:6, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or a complement thereof.
  • Another embodiment ofthe invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a BDSF nucleic acid.
  • Another aspect ofthe invention provides a vector comprising a BDSF nucleic acid molecule.
  • the vector is a recombinant expression vector.
  • the invention provides a host cell containing a vector ofthe invention.
  • the invention also provides a method for producing a protein, preferably a BDSF protein, by culturing in a suitable medium, a host cell ofthe invention containing a recombinant expression vector such that the protein is produced.
  • Another aspect of this invention features isolated or recombinant BDSF proteins and polypeptides.
  • an isolated protein, preferably a BDSF protein includes an immunoglobulin-like domain.
  • an isolated protein preferably a BDSF protein
  • an isolated protein, preferably a BDSF protein has an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.
  • an isolated protein, preferably a BDSF protein has an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:7 or SEQ ID NO: 10.
  • a protein preferably a BDSF protein, has an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO: 10.
  • the invention features fragments ofthe proteins having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, wherein the fragment comprises at least 15 contiguous amino acids ofthe amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, or an amino acid sequence encoded by the DNA insert ofthe plasmid deposited with the ATCC as Accession No. 98756.
  • the invention features fragments ofthe proteins having the amino acid sequence of SEQ ID NO:7 or SEQ ID NO: 10, wherein the fragment comprises at least 15 contiguous amino acids ofthe amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 10.
  • a protein preferably a BDSF protein, has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO: 10.
  • Another embodiment ofthe invention features an isolated protein, preferably a BDSF protein, which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 60%) homologous to a nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, or a complement thereof.
  • This invention further features an isolated protein, preferably a BDSF protein, which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, or a complement thereof.
  • Yet another embodiment ofthe invention features an isolated protein, preferably a BDSF protein, which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 60% homologous to a nucleotide sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or a complement thereof.
  • This invention further features an isolated protein, preferably a BDSF protein, which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or a complement thereof.
  • the present invention involves proteins of a novel family of G protein-coupled receptor-like proteins, referred to herein as the Seven Transmembrane Signal Transducer ("STMST" family or "STMST proteins”), as well as the nucleic acids encoding them.
  • STMST Seven Transmembrane Signal Transducer
  • the STMST molecules ofthe present invention as well as STMST ligands and/or STMST modulators, are useful in regulating a variety of cellular processes.
  • this invention provides isolated nucleic acid molecules encoding STMST proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of STMST-encoding nucleic acids.
  • an STMST nucleic acid molecule is 75% homologous to the nucleotide sequence shown in SEQ ID NO: 14, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or complement thereof. In another embodiment, an STMST nucleic acid molecule is 80% homologous to the nucleotide sequence shown in SEQ ID NO: 17, the nucleotide sequence of the
  • an isolated STMST nucleic acid molecule has the nucleotide sequence shown SEQ ID NO: 16, or a complement thereof.
  • an STMST nucleic acid molecule further comprises nucleotides 1-403 of SEQ ID NO: 1.
  • an STMST nucleic acid molecule further comprises nucleotides 1295-2915 of SEQ ID NO:14.
  • an isolated STMST nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO: 1.
  • an isolated nucleic acid molecule has the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a complement thereof.
  • an isolated STMST nucleic acid molecule has the nucleotide sequence shown SEQ ID NO: 19, or a complement thereof.
  • an STMST nucleic acid molecule further comprises nucleotides 1-333 of SEQ ID NO: 17.
  • an STMST nucleic acid molecule further comprises nucleotides 2161 -4166 of SEQ ID NO : 17.
  • an isolated STMST nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO: 17.
  • an isolated nucleic acid molecule has the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a complement thereof.
  • an STMST nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO: 15, the amino acid sequence of SEQ ID NO: 18, an amino acid or an amino acid sequence encoded by the DNA insert ofthe plasmid deposited with the ATCC as Accession No. , or an amino acid or an amino acid sequence encoded by the DNA insert ofthe plasmid deposited with the ATCC as
  • an STMST nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 75% homologous to the amino acid sequence of SEQ ID NO: 15 or an amino acid or an amino acid sequence encoded by the DNA insert ofthe plasmid deposited with the ATCC as Accession No. .
  • an STMST nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 60% homologous to the amino acid sequence of SEQ ID NO: 18 or an amino acid or an amino acid sequence encoded by the DNA insert ofthe plasmid deposited with the ATCC as Accession No. .
  • an isolated nucleic acid molecule ofthe present invention encodes an STMST protein which includes at least one transmembrane domain. In another embodiment, an isolated nucleic acid molecule ofthe present invention encodes a protein which includes a 7 transmembrane receptor profile. In another embodiment, an isolated nucleic acid molecule ofthe present invention encodes a protein which includes a spectrin ⁇ -chain motif. In yet another embodiment, an STMST nucleic acid molecule encodes an STMST protein and is a naturally occurring nucleotide sequence.
  • Another embodiment ofthe invention features STMST nucleic acid molecules which specifically detect STMST nucleic acid molecules relative to nucleic acid molecules encoding non-STMST proteins.
  • STMST nucleic acid molecules which specifically detect STMST nucleic acid molecules relative to nucleic acid molecules encoding non-STMST proteins.
  • an STMST nucleic acid molecules which specifically detect STMST nucleic acid molecules relative to nucleic acid molecules encoding non-STMST proteins.
  • STMST nucleic acid molecule is at least 350 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number , the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a complement thereof.
  • Another embodiment ofthe invention provides an isolated nucleic acid molecule which is antisense to the coding strand of an STMST nucleic acid.
  • Another aspect ofthe invention provides a vector comprising an STMST nucleic acid molecule.
  • the vector is a recombinant expression vector.
  • the invention provides a host cell containing a vector ofthe invention.
  • the invention also provides a method for producing an STMST protein by culturing in a suitable medium, a host cell ofthe invention containing a recombinant expression vector such that an STMST protein is produced.
  • Another aspect of this invention features isolated or recombinant STMST proteins and polypeptides.
  • an isolated STMST protein includes at least one transmembrane domain.
  • an isolated STMST protein includes at least six transmembrane domains.
  • an isolated STMST protein includes seven transmembrane domains. In another embodiment, an isolated STMST protein includes a 7 transmembrane receptor profile. In another embodiment, an isolated STMST protein includes a spectrin ⁇ -chain profile. In another embodiment, an isolated STMST protein has an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 18. In a preferred embodiment, an STMST protein has an amino acid sequence at least about 75%) homologous to the amino acid sequence of SEQ ID NO: 15. In another preferred embodiment, an STMST protein has an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO: 18. In another embodiment, an STMST protein has the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 18.
  • Another embodiment ofthe invention features an isolated STMST protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 75%) homologous to a nucleotide sequence of SEQ ID NO: 14, or a complement thereof.
  • Another embodiment ofthe invention features an isolated STMST protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 80% homologous to a nucleotide sequence of SEQ ID NO: 17, or a complement thereof.
  • This invention further features an isolated STMST protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 14, SEQ ID NO: 17, or a complement thereof.
  • the proteins ofthe present invention can be operatively linked to a non-BDSF or non- STMST polypeptide to form fusion proteins.
  • the invention further features antibodies that specifically bind BDSF or STMST proteins, such as monoclonal or polyclonal antibodies.
  • the BDSF or STMST proteins or biologically active portions thereof can be inco ⁇ orated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.
  • the present invention provides a method for detecting BDSF or
  • the present invention provides a method for detecting the presence of BDSF or STMST activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of BDSF or STMST activity such that the presence of BDSF or STMST activity is detected in the biological sample.
  • the invention provides a method for modulating BDSF or STMST activity comprising contacting the cell with an agent that modulates BDSF or STMST activity such that BDSF or STMST activity in the cell is modulated.
  • the agent inhibits BDSF or STMST activity.
  • the agent stimulates BDSF or STMST activity.
  • the agent is an antibody that specifically binds to a BDSF or STMST protein.
  • the agent modulates expression of BDSF or STMST by modulating transcription of a BDSF or STMST gene or translation of a BDSF or STMST mRNA.
  • the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a BDSF or STMST mRNA or a BDSF or STMST gene.
  • the methods ofthe present invention are used to treat a subject having a disorder characterized by aberrant BDSF or STMST protein or nucleic acid expression or activity by administering an agent which is a BDSF or STMST modulator to the subject.
  • the BDSF or STMST modulator is a BDSF or STMST protein, respectively.
  • the BDSF or STMST modulator is a BDSF or STMST nucleic acid molecule, respectively.
  • the STMST modulator is an STMST ligand.
  • the BDSF or STMST modulator is a peptide, peptidomimetic, or other small molecule.
  • the disorder characterized by aberrant BDSF protein or nucleic acid expression is a proliferative or differentiative disorder.
  • the disorder characterized by aberrant STMST protein or nucleic acid expression is a developmental, differentiative, proliferative disorder, an inflammatory disorder, a respiratory disorder (e.g., asthma), or cell death.
  • the present invention also provides a diagnostic assay for identifying the presence or absence of a genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding a STMST protein; (ii) mis-regulation of said gene; and (iii) aberrant post-translational modification of a BDSF or STMST protein, wherein a wild-type form of said gene encodes an protein with a BDSF or STMST activity, respectively.
  • the invention provides a method for identifying a compound that binds to or modulates the activity of a BDSF or STMST protein.
  • the invention provides a method for identifying a compound which binds to a BDSF or STMST protein which involves contacting the BDSF or STMST protein, or a cell expressing the BDSF or STMST protein with a test compound and determining whether the BDSF or STMST protein binds to the test compound.
  • the invention provides a method for identifying a compound which modulates the activity of a BDSF or STMST protein which involves contacting a BDSF or STMST protein with a test compound, and determining the effect ofthe test compound on the activity ofthe polypeptide to thereby identify a compound which modulates the activity ofthe BDSF or STMST protein.
  • Figure 1 depicts the cDNA sequence and predicted amino acid sequence of human BDSF-1.
  • the nucleotide sequence corresponds to nucleic acids 1 to 1119 of SEQ ID NO: 1.
  • the amino acid sequence corresponds to amino acids 1 to 244 of SEQ ID NO.2.
  • Figure 2 depicts the cDNA sequence and predicted amino acid sequence of murine BDSF-1.
  • the nucleotide sequence corresponds to nucleic acids 1 to 3196 of SEQ ID NO:6.
  • the amino acid sequence corresponds to amino acids 1 to 251 of SEQ ID NO:7.
  • Figure 3 depicts an alignment ofthe amino acid sequence of human BDSF-1, corresponding to SEQ ID NO:2, with the amino acid sequence of murine BDSF-1, corresponding to SEQ ID NO:7.
  • the immunoglobulin-like domains are underlined.
  • the conserved cysteine residues ofthe immunoglobulin-like domain of human and murine BDSF are indicated with an asterix.
  • the alignment was performed using the ALIGN program with a PAM120 weight residue table, a gap length penalty of 12, and a gap penatly of 4.
  • Figure 4 depicts the cDNA sequence and predicted amino acid sequence of human STMST- 1.
  • the nucleotide sequence corresponds to nucleic acids 1 to 2915 of SEQ ID NO: 14.
  • the amino acid sequence corresponds to amino acids 1 to297 of SEQ ID NO: 15.
  • Figure 5 depicts the cDNA sequence and predicted amino acid sequence of human STMST-2.
  • the nucleotide sequence corresponds to nucleic acids 1 to 4166 of SEQ ID NO: 17.
  • the amino acid sequence corresponds to amino acids 1 to 609 of SEQ ID NO: 18.
  • Figure 6 depicts an alignment ofthe amino acid sequences of human STMST- 1 (SEQ ID NO: 15), human STMST-2 (SEQ ID NO: 18), human protein A-2 (Accession No. U47928, SEQ ID NO:29), and human protein A-3 (Accession No. U47929, SEQ ID NO:30).
  • the 7 transmembrane receptor profile is indicated in italics.
  • the transmembrane domains are underlined.
  • the spectrin ⁇ -chain profile is indicated in bold.
  • the present invention is based on the discovery of novel molecules, referred to herein as BDSF protein and nucleic acid molecules, which comprise a family of molecules having certain conserved structural and functional features.
  • novel molecules referred to herein as STMST protein and nucleic acid molecules, which comprise a second family of molecules having certain conserved structural and functional features.
  • family when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein.
  • family members can be naturally occurring and can be from either the same or different species.
  • a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin.
  • Members of a family may also have common functional characteristics.
  • Members of a family may also share sufficient sequence homology with other members ofthe same family.
  • isolated proteins ofthe present invention preferably BDSF proteins
  • isolated proteins of the present invention preferably STMST proteins, have an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 18.
  • the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity.
  • amino acid or nucleotide sequences which share common structural domains have at least about 30-40%> homology, preferably 40-50% homology, more preferably 50-60%, and even more preferably 60-70%, 70-80%, or 80-90%> homology across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently homologous.
  • amino acid or nucleotide sequences which share at least 30-40%), preferably 40-50%>, more preferably 50-60%, 60-70%, 70-80%), or 80-90% homology and share a common functional activity are defined herein as sufficiently homologous.
  • the BDSF proteins ofthe present invention belong to a family of signaling proteins having common structural and functional characteristics.
  • the isolated proteins ofthe present invention preferably BDSF proteins, are proteins having an amino acid sequence of about 150-340 amino acid residues in length, preferably about 170-320, more preferably about 190-300, more preferably about 210-280, or about 230-260 amino acid residues in length.
  • an isolated protein ofthe present invention preferably a BDSF protein, includes an immunoglobulin (Ig)-like domain.
  • an "immunoglobulin-like domain” includes an amino acid sequence having about 65-115, preferably about 70- 110, more preferably about 80-100 amino acid residues, and even more preferably at least about 85-95 amino acids in length and having a bit score for the alignment ofthe sequence to the Ig family Hidden Markov Model (HMM) of at least 10, preferably 10- 15, more preferably 15-20, more preferably 20-25, even more preferably 25-35, 35-55, 55-100 or greater.
  • HMM Hidden Markov Model
  • the Ig family HMM has been assigned the PFAM Accession PF00047 (http://genome.wustl.edu Pfam/WWWdata/ig.html).
  • the amino acid sequence ofthe family member is searched against a database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters (http://www.sanger.ac.uk Software/Pfam/HMM_search).
  • HMMs e.g., the Pfam database, release 2.1
  • the default parameters http://www.sanger.ac.uk Software/Pfam/HMM_search.
  • the hmmsf program which is available as part ofthe HMMER package of search programs, is a family specific default program for PF00047 having a score of 15 as the default threshold score for determining a hit.
  • a search using the amino acid sequence of SEQ ID NO:2 was performed against the HMM database resulting in the identification of an Ig-like domain in the amino acid sequence of SEQ ID NO:2 and a score of 22.43 against the Ig family HMM Accession PF00047.
  • the results ofthe search are set forth below.
  • a search was performed using the amino acid sequence of SEQ ID NO:7 against the HMM database resulting in the identification of an Ig-like domain in the amino acid sequence of SEQ ID NO:7 and a score of 22.43 against the Ig family HMM Accession PF00047. The results ofthe search are set forth below.
  • a BDSF protein is a human BDSF-1 protein having an Ig-like domain at about amino acids 41-129 of SEQ ID NO:2.
  • Such an Ig-like domain has the amino acid sequence:
  • BDSF family members having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%>, or about 80-90%) homology with the Ig-like domain of human BDSF-1 (e.g., SEQ ID NO:l 1) are within the scope of the invention.
  • a BDSF protein is a murine BDSF-1 protein having an Ig-like domain at about amino acids 40-128 of SEQ ID NO:7.
  • Such an Ig-like domain has the amino acid sequence:
  • BDSF family member having at least 50-60% homology, preferably about 60-70%), more preferably about 70-80%), or about 80-90%> homology with the Ig-like domain of murine BDSF-1 (e.g., SEQ ID NO:12) is within the scope of the invention.
  • Description ofthe Pfam database can be found in Sonhammer et al.
  • An Ig-like domain further contains at least one, preferably two, cysteine residues which are conserved between BDSF molecules.
  • the Ig-like domain of a protein preferably a BDSF protein
  • a protein preferably a BDSF protein
  • cysteine residues which are located in the same or similar positions as cysteine residues in other BDSF protein family members.
  • preferred cysteine residues ofthe invention are those in which cysteine residues in the amino acid sequence of BDSF are located in the same or similar position as the cysteine residues in other BDSF family members.
  • cysteine residues located in the same or similar positions ofthe human BDSF protein (corresponding to SEQ ID NO:2) and murine BDSF protein (corresponding to SEQ ID NO:7) in the following locations: amino acid number 48 of human BDSF and amino acid number 47 of murine BDSF; and amino acid number 127 of human BDSF and amino acid number 126 of murine BDSF.
  • a BDSF protein has an Ig-like domain and a signal sequence.
  • a signal sequence refers to a peptide of about 20-30 amino acid residues in length which occurs at the N-terminus of secretory and integral membrane proteins and which contains a majority of hydrophobic amino acid residues.
  • a signal sequence contains at least about 15-45 amino acid residues, preferably about 20-40 amino acid residues, more preferably about 20-30 amino acid residues, and more preferably about 24-28 amino acid residues, and has at least about 40-70%), preferably about 50-65%>, and more preferably about 55-60%) hydrophobic amino acid residues (e.g., Alanine, Valine, Leucine, Isoleucine, Phenylalanine, Tyrosine, Tryptophan, or Proline).
  • a signal sequence also referred to in the art as a "signal peptide" serves to direct a protein containing such a sequence to a lipid bilayer.
  • a BDSF protein contains a signal sequence of about amino acids 1-25 of SEQ ID NO:2, or a signal sequence of about amino acids 1 -24 of SEQ ID NO:7.
  • BDSF activity refers to an activity exerted by a BDSF protein, polypeptide or nucleic acid molecule as determined in vivo, or in vitro, according to standard techniques.
  • a BDSF activity is a direct activity, such as an association with a BDSF-target molecule.
  • target molecule is a molecule with which a BDSF protein binds or interacts in nature (e.g., a BDSF receptor), such that BDSF-mediated function is achieved.
  • a BDSF target molecule can be a BDSF protein or polypeptide ofthe present invention or a non-BDSF molecule.
  • a BDSF activity is an indirect activity, such as an activity mediated by interaction ofthe BDSF protein with a BDSF target molecule such that the target molecule modulates a downstream cellular activity (e.g., interaction of an BDSF molecule with a BDSF target molecule can modulate the activity of that target molecule on an intracellular signaling pathway).
  • a BDSF activity is at least one or more ofthe following activities: (i) interaction of a BDSF protein in the extracellular milieu with a non-BDSF protein molecule on the surface ofthe same cell which secreted the BDSF protein molecule; (ii) interaction of a BDSF protein in the extracellular milieu with a non-BDSF protein molecule on the surface of a different cell from that which secreted the BDSF protein molecule; (iii) complex formation between a BDSF protein and a BDSF receptor; (iv) complex formation between a BDSF protein and non-BDSF receptor; and (v) interaction of a BDSF protein with a second protein in the extracellular milieu.
  • a BDSF activity is at least one or more ofthe following activities: (1) modulation of cellular signal transduction, either in vitro or in vivo; (2) modulation of protei protein interactions, either in vitro or in vivo; (3) regulation of cellular proliferation; or (4) regulation of cellular differentiation.
  • another embodiment ofthe invention features isolated BDSF proteins and polypeptides having a BDSF activity.
  • Preferred proteins are BDSF proteins having an Ig-like domain, and, preferably, a BDSF activity.
  • the isolated protein further comprises a signal sequence.
  • the isolated protein is a BDSF protein having an Ig-like domain, a BDSF activity, preferably an amino acid sequence sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:7, and optionally a signal sequence and/or propeptide.
  • the human BDSF-1 cDNA which is approximately 1119 nucleotides in length, encodes a protein which is approximately 244 amino acid residues in length.
  • the human BDSF-1 protein has an Ig-like domain.
  • An Ig-like domain includes, for example, about amino acids 41-129 of SEQ ID NO:2.
  • the Ig-like domain further contains at least about two conserved cysteine residues. Cysteine residues can be found at least about at amino acids 48 and 127 of SEQ ID NO:2.
  • the human BDSF-1 protein is predicted to be a secreted protein which contains a signal sequence at about amino acids 1 -25 of SEQ ID NO:2. The prediction of such a signal peptide can be made, for example, utilizing the computer algorithm SIGNALP (Henrik, et al. (1997) Protein Engineering 10:1-6).
  • the murine BDSF-1 cDNA which is approximately 3196 nucleotides in length, encodes a protein which is approximately 251 amino acid residues in length.
  • the murine BDSF-1 protein has an Ig-like domain.
  • An Ig-like domain includes, for example, about amino acids 40-128 of SEQ ID NO:7.
  • the Ig-like domain further contains at least about two conserved cysteine residues. Cysteine residues can be found at least about at amino acids 47 and 126 of SEQ ID NO:7.
  • the murine BDSF-1 protein is predicted to be a secreted protein which contains a signal sequence at about amino acids 1-24 of SEQ ID NO:7.
  • Human BDSF maps to hu7pl2-14 between markers WI-967 and WI-4253 close to the CMT2D (Charcot-Marie-Tooth neuropathy) locus.
  • BDSF The syntenic chromosome in mouse, mol 1, is in close proximity with the mouse known genes: egfr (epidermal growth factor receptor), ddc (dopa decarboxylase) and cobl (cordondian)).
  • BDSF also maps close to the following human genes: ADCYAP1R1 (adenylate cyclase activating polypeptide 1), AMPH (amphiphysin), BLVRA (biliverdin reductase A), OGDH (oxoglutarate dehydrogenase), OCM (oncomodulin) and EGFR (epidermal growth factor receptor).
  • regulation and/or modulation of BDSF can play an important role in the following: (1) regulation of neuronal proliferation and/or differentiation; (2) modulation of neuronal signaling; (3) regulation of neurodegeneration (e.g. , modulation of apoptotic degeneration and/or neuron atrophy); and (4) regulation of neurotoxicity.
  • BDSF molecules and/or modulators can provide novel therapeutic approaches for treatment of disorders and/or diseases including (1) neurodegenerative diseases (e.g., Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Huntington's Disease, Parkinson's and other Lewy diffuse body diseases, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, Jakob-Creutzfieldt disease, or AIDS related dementia; (2) peripheral neuropathies and/or demylinopathies; and (3) nervous system- related disorders and/or diseases including cognitive disorders, e.g., memory and learning disorders, such as amnesia, apraxia, agnosia, amnestic dysnomia, amnestic spatial disorientation, Kluver-Bucy syndrome, Alzheimer's related memory loss (Eglen R.M.
  • cognitive disorders e.g., memory and learning disorders, such as amnesia, apraxia, agnosia, amnes
  • GPCRs G protein-coupled receptors
  • STMST proteins ofthe present invention comprise an N-terminal extracellular domain, seven transmembrane domains (also referred to as membrane- spanning domains), three extracellular domains (also referred to as extracellular loops), three cytoplasmic domains (also referred to as cytoplasmic loops), and a C-terminal cytoplasmic domain (also referred to as a cytoplasmic tail).
  • GPCRs G protein-coupled receptors
  • Members ofthe GPCR family also share certain conserved amino acid residues, some of which have been determined to be critical to receptor function and or G protein signaling.
  • GPCRs contain the following features: a conserved asparagine residue in the first transmembrane domain; a cysteine residue in the first extracellular loop which is believed to form a disulfide bond with a conserved cysteine residue in the second extracellular loop; a conserved leucine and aspartate residue in the second transmembrane domain; an aspartate-arginine-tyrosine motif (DRY motif) at the interface ofthe third transmembrane domain and the second cytoplasmic loop of which the arginine residue is almost invariant (members ofthe rhodopsin subfamily of GPCRs comprise a histidine-arginine-methionine motif (HRM motif) as compared to a DRY motif); a conserved tryptophan and proline residue in the fourth transmembrane domain; a conserved phenylalanine residue which is commonly found as part ofthe motif FXXCXXP; and a conserved leucine residue in the seventh
  • Table I depicts an alignment ofthe transmembrane domains of 5 GPCRs. The conserved residues described herein are indicated by asterices. An alignment ofthe transmembrane domains of 44 representative GPCRs can be found at http://mgdkkl .nidll.nih.gov:8000/extended.html.
  • IL-8A (30.) human P25024 octopamine (40.) Drosophila melanogaster P22270
  • thrombin receptor accesion No. P25116
  • rhodopsin receptor accesion No. P08100
  • ml ACh receptor accesion No. P08482
  • IL-8A receptor accesion No. P25024
  • octopamine receptor accesion No. P22270
  • SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO: 145 are set forth as SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO: 145, respectively.
  • GPCR-like proteins such as the STMST proteins ofthe present invention contain a significant number of structural characteristics ofthe GPCR family.
  • the STMSTs ofthe present invention contain conserved cysteines found in the first 2 extracellular loops (prior to the third and fifth transmembrane domains) of most GPCRs (cys 83 and cys 161 of SEQ ID NO: 15 or SEQ ID NO: 18).
  • a highly conserved asparagine residue in the first transmembrane domain is present (asn25 in SEQ ID NO: 15 or SEQ ID NO: 18).
  • Transmembrane domain two ofthe STMST proteins contains a highly conserved leucine (leu49 of SEQ ID NO: 15 or SEQ ID NO: 18). The two cysteine residues are believed to form a disulfide bond that stabilizes the functional protein structure.
  • a highly conserved tryptophan and proline in the fourth transmembrane domain ofthe STMST proteins is present (trpl35 and pro 145 of SEQ ID NO:15 or SEQ ID NO:18).
  • the third cytoplasmic loop contains 49 amino acid residues and is thus the longest cytoplasmic loop ofthe three, characteristic of G protein coupled receptors.
  • a highly conserved proline in the sixth transmembrane domain is present (pro260 of SEQ ID NO: 15 and SEQ ID NO: 18).
  • the proline residues in the fourth, fifth, sixth, and seventh transmembrane domains are thought to introduce kinks in the alpha-helices and may be important in the formation ofthe ligand binding pocket.
  • the conserved (in the second cytoplasmic loop) HRM motif found in almost all Rhodopsin family GPCRs is present in the STMST proteins ofthe instant invention (hisl07, argl08, metl09 of SEQ ID NO: 15 or SEQ ID NO: 18).
  • the arginine ofthe HRM sequence is thought to be the most important amino acid in GPCRs and is invariant).
  • an almost invariant proline is present in the seventh transmembrane domain of STMST-2 (pro294 of SEQ ID NO:18).
  • the STMST proteins ofthe present invention are proteins having an amino acid sequence of about 150-450, preferably about 200-400, more preferably about 225-375, more preferably about 250-350, or about 275-325 amino acids in length. In another embodiment, the STMST proteins ofthe present invention are proteins having an amino acid sequence of about 450-750, preferably about 500-700, more preferably about 525-675, even more preferably about 550-650, and even more preferably about 575-625 amino acid residues in length. In one embodiment, the STMST proteins ofthe present invention contain at least one transmembrane domain.
  • transmembrane domain includes an amino acid sequence having at least about 10, preferably about 13, preferably about 16, more preferably about 19, 21, 23, 25, 30, 35 or 40 amino acid residues, of which at least about 50-60%), 60- 70%>, preferably about 70-80%> more preferably about 80-90%, or about 90-95% ofthe amino acid residues contain non-polar side chains, for example, alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.
  • a transmembrane domain is lipophillic in nature. For example, a transmembrane domain can be found at about amino acids 11-34 of SEQ ID NO: 15 or SEQ ID NO: 18.
  • an STMST protein ofthe present invention has more than one transmembrane domain, preferably 2, 3, 4, 5, 6, or 7 transmembrane domains.
  • transmembrane domains can be found at about amino acids 11-34, 44-67, 85- 106, 127-149, 172-196, and 244-262 of SEQ ID NO: 15 as well as at 11-34, 44-67, 85- 106, 127-149, 172-196, 245-269, and 277-300 of SEQ ID NO:18.
  • an STMST protein ofthe present invention has 7 transmembrane domains.
  • an STMST family member is identified based on the presence of at least one cytoplasmic loop, also referred to herein as a cytoplasmic domain.
  • an STMST family member is identified based on the presence of at least one extracellular loop.
  • the term "loop" includes an amino acid sequence having a length of at least about 4, preferably about 5-10, preferably about 10-20, and more preferably about 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, or 100-150 amino acid residues, and has an amino acid sequence that connects two transmembrane domains within a protein or polypeptide.
  • the N-terminal amino acid of a loop is adjacent to a C-terminal amino acid of a transmembrane domain in a naturally-occurring GPCR or GPCR-like molecule
  • the C-terminal amino acid of a loop is adjacent to an N-terminal amino acid of a transmembrane domain in a naturally-occurring GPCR or GPCR-like molecule.
  • a "cytoplasmic loop” includes an amino acid sequence located within a cell or within the cytoplasm of a cell.
  • a cytoplasmic loop is found at about amino acids 35-43, 107-126, and 197-243 of SEQ ID NO: 15, or alternatively, at about amino acid residues 35-43, 107-126, and 197-244 of SEQ ID NO:18.
  • an "extracellular loop” includes an amino acid sequence located outside of a cell, or extracellularly.
  • an extracellular loop can be found at about amino acid residues 68-84 and 150-171 of SEQ ID NO: 15, or alternatively, at about amino acid residues 86-84, 150-171, or 270-276 of SEQ ID NO: 18.
  • an STMST family member is identified based on the presence of a "C-terminal cytoplasmic domain", also referred to herein as a C-terminal cytoplasmic tail, in the sequence ofthe protein.
  • a "C- terminal cytoplasmic domain” includes an amino acid sequence having a length of at least about 10, preferably about 10-25, more preferably about 25-50, more preferably about 50-75, even more preferably about 75-100, 100-150, 150-200, 200-250, 250-300, 300-400, 400-500, or 500-600 amino acid resudues and is located within a cell or within the cytoplasm of a cell.
  • the N-terminal amino acid residue of a "C- terminal cytoplasmic domain” is adjacent to a C-terminal amino acid residue of a transmembrane domain in a naturally-occurring GPCR or GPCR-like protein.
  • a C-terminal cytoplasmic domain is found at about amino acid residues 301- 609 of SEQ ID NO: 18.
  • an STMST family member is identified based on the presence of an "N-terminal extracellular domain", also referred to herein as an N- terminal extracellular loop in the amino acid sequence ofthe protein.
  • an "N-terminal extracellular domain” includes an amino acid sequence having about 1-500, preferably about 1-400, more preferably about 1-300, more preferably about 1-200, even more preferably about 1-100, and even more preferably about 1-50, 1-25, or 1-10 amino acid residues in length and is located outside of a cell or extracellularly.
  • N-terminal extracellular domain is adjacent to an N-terminal amino acid residue of a transmembrane domain in a naturally-occurring GPCR or GPCR-like protein.
  • an N-terminal cytoplasmic domain is found at about amino acid residues 1-10 of SEQ ID NO:15 or SEQ ID NO:18.
  • an STMST family member includes at least one, preferably 6 or 7, transmembrane domains and and/or at least one cytoplasmic loop, and/or at least one extracellular loop.
  • the STMST family member further includes an N-terminal extracellular domain and/or a C- terminal cytoplasmic domain.
  • the STMST family member can include six transmembrane domains, three cytoplasmic loops, and two extracellular loops, or can include six transmembrane domains, three extracellular loops, and 2 cytoplasmic loops.
  • the former embodiment can further include an N-terminal extracellular domain.
  • the latter embodiment can further include a C-terminal cytoplasmic domain.
  • the STMST family member can include seven transmembrane domains, three cytoplasmic loops, and three extracellular loops and can further include an N-terminal extracellular domain or a C-terminal cytoplasmic domain.
  • an STMST family member is identified based on the presence of at least one "7 transmembrane receptor profile", also referred to as a "Rhodopsin family sequence profile", in the protein or corresponding nucleic acid molecule.
  • the term "7 transmembrane receptor profile” includes an amino acid sequence having at least about 100-400, preferably about 150-350, more preferably about 200-300 amino acid residues, or at least about 250-275 amino acids in length and having a bit score for the alignment ofthe sequence to the 7tm_l family Hidden Markov Model (HMM) of at least 20, preferably 20-30, more preferably 30-40, more preferably 40-50, 50-75, 75-100, 100-200 or greater.
  • HMM Hidden Markov Model
  • the amino acid sequence ofthe protein family member is searched against a database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters (http://www.sanger.ac.uk/Software/Pfam/HMM_search).
  • HMMs e.g., the Pfam database, release 2.1
  • the default parameters http://www.sanger.ac.uk/Software/Pfam/HMM_search.
  • the hmmsf program which is available as part ofthe HMMER package of search programs, is a family specific default program for PFOOOOl and score of 15 is the default threshold score for determining a hit.
  • a search using the amino acid sequence of SEQ ID NO: 15 was performed against the HMM database resulting in the identification of a 7 TM receptor profile in the amino acid sequence of SEQ ID NO: 15. The results of the search are set forth below.
  • an STMST protein is a human STMST- 1 or a human STMST-2 protein having a 7 transmembrane receptor profile at about amino acids 24-191 of SEQ ID NO:15 or SEQ ID NO:18, respectively.
  • Such a 7 transmembrane receptor profile has the amino acid sequence:
  • STMST family members having at least 50-60%> homology, preferably about 60-70%>, more preferably about 70-80%>, or about 80-90%) homology with the 7 transmembrane receptor profile of human STMST- 1 or STMST-2 (e.g., SEQ ID NO:22) are within the scope ofthe invention.
  • an STMST family member is identified based on the presence of a "spectrin ⁇ -chain profile" in the protein or corresponding nucleic acid molecule.
  • the term "spectrin ⁇ -chain profile” includes a protein domain having an amino acid sequence of about 50-250, preferably about 75-225, more preferably about 100-200 amino acid residues, or about 125-175 amino acids and having a bit score for the alignment ofthe sequence to the spectrin family (HMM) of at least 7, preferably 8-10, more preferably 10-30, more preferably 30-50, even more preferably 50-75, 75-100, 100-200 or greater.
  • the spectrin family HMM has been assigned the PFAM Accession PF00435 (http://genome.wustl.edu/Pfam/WWWdata/spectrin.html).
  • PFAM Accession PF00435 http://genome.wustl.edu/Pfam/WWWdata/spectrin.html.
  • the amino acid sequence ofthe protein is searched against a database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters
  • the hmmsf program which is available as part ofthe HMMER package of search programs, is a family specific default program for PF00435 and a score of 15 is the default threshold score for determining a hit.
  • the threshold score for determining a hit can be lowered (e.g., to 8 bits).
  • a description ofthe Pfam database can be found in Sonhammer et al. (1997) Proteins 28(3)405-420 and a detailed description of HMMs can be found, for example, in Gribskov et ⁇ /.(1990) Meth. Enzymol.
  • an STMST protein is human STMST-2 protein which includes a spectrin ⁇ -chain profile at about amino acids 266-372 of SEQ ID NO:
  • Such a spectrin ⁇ -chain profile has the amino acid sequence:
  • STMST family members having at least 50-60%> homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a spectrin ⁇ -chain profile of human STMST-2 (e.g., SEQ ID NO:23) are within the scope ofthe invention.
  • an STMST protein includes at least a spectrin ⁇ -chain profile. In another embodiment, an STMST protein includes a spectrin ⁇ -chain profile and a 7 transmembrane receptor profile. In another embodiment, an STMST protein is human STMST-2 which includes a spectrin ⁇ -chain profile having about amino acids 266-372 of SEQ ID NO: 18. In yet another embodiment, an STMST protein is human STMST-2 which includes a 7 transmembrane receptor profile having about amino acids 24-191 of SEQ ID NO: 18 and a spectrin ⁇ -chain profile having about amino acids 266-372 of SEQ ID NO: 18.
  • an "STMST activity”, “biological activity of STMST” or “functional activity of STMST”, refers to an activity exerted by an STMST protein, polypeptide or nucleic acid molecule on an STMST responsive cell as determined in vivo, or in vitro, according to standard techniques.
  • an STMST activity is a direct activity, such as an association with an STMST-traget molecule.
  • a "target molecule” or “binding partner” is a molecule with which an STMST protein binds or interacts in nature, such that STMST-mediated function is acheived.
  • An STMST target molecule can be a non-STMST molecule or an STMST protein or polypeptide ofthe present invention.
  • an STMST target molecule is an STMST ligand.
  • an STMST activity is an indirect activity, such as a cellular signaling activity mediated by interaction ofthe STMST protein with an STMST ligand.
  • an STMST activity is at least one or more ofthe following activities: (i) interaction of an STMST protein with soluble STMST ligand; (ii) interaction of an STMST protein with a membrane-bound non-STMST protein; (iii) interaction of an STMST protein with an intracellular protein (e.g., an intracellular enzyme or signal transduction molecule); and (iv) indirect interaction of an STMST protein with an intracellular protein (e.g., a downstream signal transduction molecule.
  • an STMST activity is at least one or more ofthe following activities: (1) modulation of cellular signal transduction, either in vitro or in vivo; (2) regulation of gene transcription in a cell expressing an STMST protein; (3) regulation of gene transcription in a cell expressing an STMST protein, wherein said cell is involved inflammation; (4) regulation of cellular proliferation; (5) regulation of cellular differentiation; (6) regulation of develpoment; (7) regulation of cell death; (8) regulation of regulation of inflammation; (9) regulation of respiratory cell function (e.g., asthma); (10) regulation of actin binding; (11) regulation of cytoskeletal attachment; and (12) regulation of chemotaxis, trafficking and/or migration.
  • another embodiment ofthe invention features isolated STMST proteins and polypeptides having an STMST activity.
  • Preferred STMST proteins have at least one transmembrane domain and an STMST activity.
  • an STMST protein has a 7 transmembrane receptor profile and an STMST activity.
  • an STMST protein has a spectrin ⁇ -chain profile and an STMST activity.
  • an STMST protein has a 7 transmembrane receptor profile, a spectrin ⁇ -chain profile, and STMST activity.
  • an STMST protein has a 7 transmembrane receptor profile, a spectrin ⁇ -chain profile, an STMST activity, and an amino acid sequence sufficiently homologous to an amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO:21, or SEQ ID NO:24.
  • the human STMST- 1 cDNA which is approximately 2915 nucleotides in length, encodes a protein which is approximately 297 amino acid residues in length.
  • the human STMST- 1 protein contains 6 transmembrane domains at about amino acids 11-34, 44-67, 85-106, 127-149, 172-196, and 244-262 of SEQ ID NO: 15
  • the human STMST- 1 protein further contains a 7 transmembrane receptor profile.
  • the 7 transmembrane receptor profile can be found at least, for example, from about amino acids 24-191 of SEQ ID NO: 15.
  • the human STMST-2 cDNA which is approximately 4166 nucleotides in length, encodes approximately 609 amino acid residues ofthe human STMST- 1 protein.
  • the human STMST-2 protein contains 7 transmembrane domains at about amino acids 11-34, 44-67, 85-106, 127-149, 172-196, 245-269, and 277-300 of SEQ ID NO:18.
  • the human STMST-2 protein further contains a 7 transmembrane receptor profile.
  • the 7 transmembrane receptor profile can be found at least, for example, from about amino acids 24-191 of SEQ ID NO: 18.
  • the human STMST protein contains a spectrin ⁇ -chain profile from about amino acids 266-372 of SEQ ID NO:5.
  • One aspect ofthe invention pertains to isolated nucleic acid molecules that encode BDSF proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify BDSF-encoding nucleic acids (e.g., BDSF mRNA) and fragments for use as PCR primers for the amplification or mutation of BDSF nucleic acid molecules.
  • Another aspect ofthe invention pertains to isolated nucleic acid molecules that encode STMST proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify STMST-encoding nucleic acids (e.g., STMST mRNA) and fragments for use as PCR primers for the amplification or mutation of STMST nucleic acid molecules.
  • nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs ofthe DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • an “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source ofthe nucleic acid.
  • an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends ofthe nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived.
  • the isolated BDSF nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA ofthe cell from which the nucleic acid is derived.
  • an "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • a nucleic acid molecule ofthe present invention preferably a BDSF or STMST nucleic acid molecule, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion ofthe nucleic acid sequence of a BDSF or STMST nucleic acid molecule ofthe present invention, as a hybridization probe, BDSF or STMST nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • nucleic acid molecule encompassing all or a portion of a BDSF or STMST nucleic acid molecule, can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence ofthe BDSF or STMST nucleic acid molecules described herein.
  • a nucleic acid ofthe invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to BDSF or STMST nucleotide sequences can be prepared by standard synthetic techniques, e.g. , using an automated DNA synthesizer.
  • an isolated nucleic acid molecule ofthe invention comprises the nucleotide sequence shown in SEQ ID NO: 1.
  • the sequence of SEQ ID NO: 1 corresponds to the human BDSF cDNA.
  • This cDNA comprises sequences encoding the human BDSF protein (i.e., "the coding region", from nucleotides 140-871), as well as 5' untranslated sequences (nucleotides 1-139) and 3' untranslated sequences (nucleotides 872-1119).
  • the nucleic acid molecule can comprise only the coding region of SEQ ID NO:l (e.g., nucleotides 140-871, corresponding to SEQ ID NO:3).
  • an isolated nucleic acid molecule ofthe invention comprises the nucleotide sequence shown in SEQ ID NO:6.
  • the sequence of SEQ ID NO:6 corresponds to the murine BDSF cDNA.
  • This cDNA comprises sequences encoding the murine BDSF protein (i.e., "the coding region", from nucleotides 268-1020), as well as 5' untranslated sequences (nucleotides 1-267) and 3' untranslated sequences (nucleotides 1021-3196).
  • the nucleic acid molecule can comprise only the coding region of SEQ ID NO:6 (e.g., nucleotides 268- 1020, corresponding to SEQ ID NO: 8).
  • an isolated nucleic acid molecule ofthe invention comprises a nucleic acid molecule which is a complement ofthe nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or a portion of any of these nucleotide sequences.
  • a nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number 98756 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number
  • an isolated nucleic acid molecule ofthe present invention comprises a nucleotide sequence which is at least about 30-35%>, preferably about 35-40%), more preferably at least about 40-45%, more preferably at least about 45-50%), and even more preferably at least about 50-55%>, 55-60%>, 60-65%), 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, or 90-95% or more homologous to the nucleotide sequences shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or a portion of any of these nucleotide sequences.
  • the nucleic acid molecule ofthe invention can comprise only a portion ofthe nucleic acid sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number 98756, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a BDSF protein.
  • the nucleotide sequence determined from the cloning ofthe BDSF genes allows for the generation of probes and primers designed for use in identifying and/or cloning other BDSF family members, as well as BDSF homologues from other species.
  • the probe/primer typically comprises substantially purified oligonucleotide.
  • the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, of an anti-sense sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or of a naturally occurring mutant of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nu
  • a nucleic acid molecule ofthe present invention comprises a nucleotide sequence which is about 450, preferably 450-750, more preferably 750-950, more preferably 950-1100, and even more preferably 1100-1150 nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756.
  • Probes based on the BDSF nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins.
  • the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co- factor.
  • Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a BDSF protein, such as by measuring a level of a BDSF- encoding nucleic acid in a sample of cells from a subject e.g., detecting BDSF mRNA levels or determining whether a genomic BDSF gene has been mutated or deleted.
  • a nucleic acid fragment encoding a "biologically active portion of a BDSF protein” can be prepared by isolating a portion ofthe nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, which encodes a polypeptide having a BDSF biological activity (the biological activities ofthe BDSF proteins have previously been described), expressing the encoded portion ofthe BDSF protein (e.g., by recombinant expression in vitro) and assessing the activity ofthe encoded portion ofthe BDSF protein.
  • the invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number 98756, due to degeneracy of the genetic code and thus encode the same BDSF proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number 98756.
  • an isolated nucleic acid molecule ofthe invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:7.
  • SEQ ID NO: 1 amino acid sequence shown in SEQ ID NO: 1 .
  • DNA sequence polymo ⁇ hisms that lead to changes in the amino acid sequences ofthe BDSF proteins may exist within a population (e.g. , the human population).
  • Such genetic polymo ⁇ hism in the BDSF genes may exist among individuals within a population due to natural allelic variation.
  • the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a BDSF protein (or STMST protein), preferably a mammalian BDSF protein (or STMST protein).
  • BDSF protein or STMST protein
  • STMST protein preferably a mammalian BDSF protein (or STMST protein).
  • Such natural allelic variations can typically result in 1-5%) variance in the nucleotide sequence of a BDSF gene (or STMST gene). Any and all such nucleotide variations and resulting amino acid polymo ⁇ hisms in BDSF genes (and STMST genes) that are the result of natural allelic variation and that do not alter the functional activity of a BDSF protein (or STMST protein, respectively) are intended to be within the scope ofthe invention.
  • nucleic acid molecules encoding other BDSF family members and thus which have a nucleotide sequence which differs from the BDSF sequences of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, are intended to be within the scope ofthe invention.
  • a BDSF cDNA can be identified based on the nucleotide sequence of human BDSF or the nucleotide sequence of murine BDSF.
  • nucleic acid molecules encoding BDSF proteins from different species and thus which have a nucleotide sequence which differs from the human BDSF sequences of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, or which differs from the murine BDSF sequences of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:9 are intended to be within the scope ofthe invention.
  • a rat BDSF cDNA can be identified based on the nucleotide sequence of a human or murine BDSF.
  • Nucleic acid molecules corresponding to natural allelic variants and homologues ofthe BDSF cDNAs ofthe invention can be isolated based on their homology to the BDSF nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
  • an isolated nucleic acid molecule ofthe invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756.
  • the nucleic acid is at least 30, 50, 100, 250 or 500 nucleotides in length.
  • hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60%> homologous to each other typically remain hybridized to each other.
  • the conditions are such that sequences at least about 70%>, more preferably at least about 80%>, even more preferably at least about 85%> or 90%> homologous to each other typically remain hybridized to each other.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • a preferred, non- limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1%) SDS at 50-65°C.
  • SSC sodium chloride/sodium citrate
  • an isolated nucleic acid molecule ofthe invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:l or SEQ ID NO:6 corresponds to a naturally-occurring nucleic acid molecule.
  • a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
  • allelic variants ofthe BDSF sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, thereby leading to changes in the amino acid sequence ofthe encoded BDSF proteins, without altering the functional ability ofthe BDSF proteins.
  • nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number 98756.
  • a "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of BDSF (e.g., the sequence of SEQ ID NO: 2 or SEQ ID NO: 7) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.
  • amino acid residues that are conserved among the BDSF proteins ofthe present invention are predicted to be particularly unamenable to alteration (e.g., the conserved cysteines set forth in Figure 3).
  • amino acid residues that are defined by the Ig-like domain profile sequence are particularly unamenable to alteration.
  • additional amino acid residues that are conserved between the BDSF proteins ofthe present invention and other BDSF family members are particularly unamenable to alteration.
  • nucleic acid molecules encoding BDSF proteins that contain changes in amino acid residues that are not essential for activity.
  • BDSF proteins differ in amino acid sequence from SEQ ID NO:2 or SEQ ID NO:7 yet retain biological activity.
  • the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 60%> homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:7.
  • the protein encoded by the nucleic acid molecule is at least about 65-70% homologous to SEQ ID NO:2 or SEQ ID NO:7, more preferably at least about 75-80%) homologous to SEQ ID NO:2 or SEQ ID NO:7, even more preferably at least about 85-90% homologous to SEQ ID NO:2 or SEQ ID NO:7, and most preferably at least about 95% homologous to SEQ ID NO:2 or SEQ ID NO.7.
  • An isolated nucleic acid molecule encoding a BDSF protein homologous to the protein of SEQ ID NO:2 or SEQ ID NO:7 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
  • Mutations can be introduced into SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
  • sequence comparisons ofthe human BDSF-1 and murine BDSF-1 protein are 90.5%) identical over the first 211 amino acids ofthe protein which includes the Ig-like domain.
  • a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta-branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
  • a predicted nonessential amino acid residue in a BDSF protein is preferably replaced with another amino acid residue from the same side chain family.
  • mutations can be introduced randomly along all or part of a BDSF coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for BDSF biological activity to identify mutants that retain activity.
  • SEQ ID NO:l SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756
  • the encoded protein can be expressed recombinantly and the activity ofthe protein can be determined.
  • a mutant BDSF protein can be assayed for the ability to (1) modulate cellular signal transduction; (2) modulate proteimprotein interactions; (3) regulate cellular proliferation; or (4) regulate cellular differentiation.
  • a nucleic acid molecule ofthe present invention e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 14, the nucleotide sequence of SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.
  • STMST nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g. , as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • nucleic acid molecule encompassing all or a portion of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number
  • a nucleic acid ofthe invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques.
  • the nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to STMST nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • an isolated nucleic acid molecule ofthe invention comprises the nucleotide sequence shown in SEQ ID NO: 14.
  • the sequence of SEQ ID NO: 14 corresponds to the human STMST- 1 cDNA.
  • This cDNA comprises sequences encoding the human STMST- 1 protein (i.e. , "the coding region", from nucleotides 404- 1294), as well as 5' untranslated sequences (nucleotides 1-403) and 3' untranslated sequences (nucleotides 1295-2915).
  • the nucleic acid molecule can comprise only the coding region of SEQ ID NO: 14 (e.g., nucleotides 404-1294, corresponding to SEQ ID NO: 16).
  • an isolated nucleic acid molecule ofthe invention comprises the nucleotide sequence shown in SEQ ID NO: 17. The sequence of SEQ ID NO: 14 corresponds to the human STMST-2 cDNA.
  • This cDNA comprises sequences encoding the human STMST-2 protein (i.e., "the coding region”, from nucleotides 334-2160), as well as 5' untranslated sequences (nucleotides 1-333) and 3' untranslated sequences (nucleotides 2161-4166).
  • the nucleic acid molecule can comprise only the coding region of SEQ ID NO: 14 (e.g., nucleotides 334- 2160, corresponding to SEQ ID NO: 19).
  • an isolated nucleic acid molecule ofthe invention comprises a nucleic acid molecule which is a complement ofthe nucleotide sequence shown in SEQ ID NO:14, SEQ ID NO:17, the nucleotide sequence ofthe
  • DNA insert ofthe plasmid deposited with ATCC as Accession Number the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a portion of any of these nucleotide sequences.
  • DNA insert ofthe plasmid deposited with ATCC as Accession Number is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 14, SEQ ID NO: 17, or such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:14, SEQ ID NO:17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , thereby forming a stable duplex.
  • an isolated nucleic acid molecule ofthe present invention comprises a nucleotide sequence which is at least about 60-65%, preferably at least about 70-75%>, more preferable at least about 80-85%), and even more preferably at least about 90-95% or more homologous to the nucleotide sequences shown in SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert of the plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or a portion of any of these nucleotide sequences.
  • nucleic acid molecule ofthe invention can comprise only a portion ofthe nucleic acid sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with
  • the nucleotide sequence determined from the cloning ofthe STMST- 1 genes allows for the generation of probes and primers designed for use in identifying and/or cloning other STMST family members, as well as STMST homologues from other species.
  • the probe/primer typically comprises substantially purified oligonucleotide.
  • the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with
  • a nucleic acid molecule ofthe present invention comprises a nucleotide sequence which is greater that 350, 351-450, 451-550, 551-650, 651-750, or 751-850, 851-950, 951-1050, 1051-1150, or 1151-1250 nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO: 14 or SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number .
  • Probes based on the STMST nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins.
  • the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress an STMST protein, such as by measuring a level of an STMST-encoding nucleic acid in a sample of cells from a subject e.g., detecting STMST mRNA levels or determining whether a genomic STMST gene has been mutated or deleted.
  • a nucleic acid fragment encoding a "biologically active portion of an STMST protein" can be prepared by isolating a portion ofthe nucleotide sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe
  • DNA insert ofthe plasmid deposited with ATCC as Accession Number which encodes a polypeptide having an STMST biological activity (the biological activities of the STMST proteins have previously been described), expressing the encoded portion of the STMST protein (e.g., by recombinant expression in vitro) and assessing the activity ofthe encoded portion ofthe STMST protein.
  • the invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as
  • an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 15 or SE ID NO:5.
  • DNA sequence polymo ⁇ hisms that lead to changes in the amino acid sequences ofthe STMST proteins may exist within a population (e.g., the human population). Such genetic polymo ⁇ hism in the STMST genes may exist among individuals within a population due to natural allelic variation.
  • nucleic acid molecules encoding other STMST family members and thus which have a nucleotide sequence which differs from the STMST- 1 sequences of SEQ ID NO:14 or SEQ ID NO:17 are intended to be within the scope ofthe invention.
  • an STMST-3 cDNA can be identified based on the nucleotide sequence of human STMST- 1 or STMST-2.
  • nucleic acid molecules encoding STMST proteins from different species, and thus which have a nucleotide sequence which differs from the STMST sequences of SEQ ID NO: 14 or SEQ ID NO: 17 are intended to be within the scope ofthe invention.
  • an mouse STMST cDNA can be identified based on the nucleotide sequence of a human STMST.
  • Nucleic acid molecules corresponding to natural allelic variants and homologues ofthe STMST cDNAs ofthe invention can be isolated based on their homology to the STMST nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
  • an isolated nucleic acid molecule ofthe invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with
  • nucleic acid is at least 30, 50, 100, 250 or 500 nucleotides in length.
  • an isolated nucleic acid molecule ofthe invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , corresponds to a naturally-occurring nucleic acid molecule.
  • a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
  • nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , thereby leading to changes in the amino acid sequence ofthe encoded STMST proteins, without altering the functional ability ofthe STMST proteins.
  • nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:14, SEQ ID NO:17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number .
  • a "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of STMST (e.g., the sequence of SEQ ID NO: 15) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.
  • amino acid residues that are conserved among the STMST proteins ofthe present invention are predicted to be particularly unamenable to alteration.
  • amino acid residues that are defined by the 7 transmembrane signature profile and the spectrin ⁇ -chain, repeated domain signature profile are particularly unamenable to alteration.
  • additional amino acid residues that are conserved between the STMST proteins ofthe present invention and members ofthe G protein coupled receptor protein family are not likely to be amenable to alteration (e.g.
  • nucleic acid molecules encoding STMST proteins that contain changes in amino acid residues that are not essential for activity.
  • STMST proteins differ in amino acid sequence from SEQ ID NO: 15 and SEQ ID NO: 18 yet retain biological activity.
  • the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 75% homologous to the amino acid sequence of SEQ ID NO: 15.
  • the protein encoded by the nucleic acid molecule is at least about 75-80%) homologous to SEQ ID NO: 15, more preferably at least about 80-85% homologous to SEQ ID NO: 15, even more preferably at least about 85-90%> homologous to SEQ ID NO: 15, and even more preferably at least about 90-95% homologous to SEQ ID NO: 15.
  • the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 65% homologous to the amino acid sequence of SEQ ID NO: 18.
  • the protein encoded by the nucleic acid is at least about 65-70%> homologous to SEQ ID NO: 15, more preferably at least about 70- 75% homologous to SEQ ID NO: 18, even more preferably at least about 75-80%), and even more preferably at least about 80-85%, 85-90%, or 90-95%) homologous to SEQ ID NO: 18.
  • An isolated nucleic acid molecule encoding an STMST protein homologous to the protein of SEQ ID NO: 15 or SEQ ID NO: 18 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 14, SEQ ID NO: 17, or such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.
  • Mutations can be introduced into SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number , by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
  • a predicted nonessential amino acid residue in an STMST protein is preferably replaced with another amino acid residue from the same side chain family.
  • mutations can be introduced randomly along all or part of an STMST coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for STMST biological activity to identify mutants that retain activity.
  • SEQ ID NO: 14 Following mutagenesis of SEQ ID NO: 14, SEQ ID NO: 17, or the encoded protein can be expressed recombinantly and the activity ofthe protein can be determined.
  • a mutant STMST protein can be assayed for the ability to (1) modulation of cellular signal transduction, either in vitro or in vivo; (2) regulation of gene transcription in a cell expressing an STMST protein; (3) regulation of gene transcription in a cell expressing an STMST protein, wherein said cell is involved inflammation; (4) regulation of cellular proliferation; (5) regulation of cellular differentiation; (6) regulation of develpoment; (7) regulation of cell death; (8) regulation of inflammation; and (9) regulation of respiratory cell function.
  • an antisense nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire BDSF or STMST coding strand, or to only a portion thereof.
  • an antisense nucleic acid molecule is antisense to a "coding region" ofthe coding strand of a nucleotide sequence encoding a BDSF or STMST protein.
  • the term "coding region” refers to the region ofthe nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the coding region of human BDSF corresponds to SEQ ID NO:3, the coding region of murine BDSF corresponds to SEQ ID NO:8, the coding region of human STMST-1 corresponds to SEQ ID NO: 16 and the coding region of human STMST-2 corresponds to SEQ ID NO: 19).
  • the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding BDSF.
  • the term "noncoding region” refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
  • antisense nucleic acids ofthe invention can be designed according to the rules of Watson and Crick base pairing.
  • the antisense nucleic acid molecule can be complementary to the entire coding region of BDSF or STMST mRNA, but more preferably is an oligonucleotide which is antisense to only a portion ofthe coding or noncoding region of BDSF or STMST mRNA.
  • the antisense oligonucleotide can be complementary to the region surrounding the translation start site of BDSF or STMST mRNA.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability ofthe molecules or to increase the physical stability ofthe duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5- bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5- (carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2- methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7- methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta- D-mannosylqueosine, 5'-methoxycar
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
  • the antisense nucleic acid molecules ofthe invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a BDSF or STMST protein to thereby inhibit expression ofthe protein, e.g., by inhibiting transcription and/or translation.
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove ofthe double helix.
  • An example of a route of administration of antisense nucleic acid molecules ofthe invention include direct injection at a tissue site.
  • antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
  • antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens.
  • the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations ofthe antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
  • the antisense nucleic acid molecule ofthe invention is an ⁇ -anomeric nucleic acid molecule.
  • An ⁇ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641).
  • the antisense nucleic acid molecule can also comprise a 2'-o- methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al.
  • an antisense nucleic acid ofthe invention is a ribozyme.
  • Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes e.g., hammerhead ribozymes described in Haselhoff and Gerlach (1988) Nature 334:585-591
  • a ribozyme having specificity for a BDSF-encoding nucleic or STMST-encoding nucleic acid acid can be designed based upon the nucleotide sequence of a BDSF cDNA or STMST mRNA disclosed herein.
  • a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence ofthe active site is complementary to the nucleotide sequence to be cleaved in a BDSF- encoding mRNA or STMST-encoding mRNA. See, e.g., Cech et al U.S. Patent No. 4,987,071; and Cech et al U.S. Patent No. 5,116,742.
  • BDSF mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) Science 261:1411-1418.
  • BDSF or STMST gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region ofthe BDSF or STMST genes(e.g., promoter and/or enhancer sequences) to form triple helical structures that prevent transcription ofthe BDSF or STMST genes in target cells. See generally, Helene, C. (1991) Anticancer Drug Des. 6(6):569-84; Helene, C. et al ( ⁇ 992) Ann. NY. Acad. Sci. 660:27-36; and Maher, L.J. (1992) Bioassays 14(12):807-15.
  • the nucleic acid molecules ofthe present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility ofthe molecule.
  • the deoxyribose phosphate backbone ofthe nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) Bioorganic & Medicinal Chemistry 4 (1): 5-23).
  • the terms "peptide nucleic acids” or "PNAs” refer to nucleic acid mimics, e.g.
  • DNA mimics in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
  • the neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
  • the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. et al. (1996) supra; Perry-O'Keefe et al. PNAS 93: 14670-675.
  • PNAs of BDSF or STMST nucleic acid molecules can be used in therapeutic and diagnostic applications.
  • PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication.
  • PNAs of BDSF or STMST nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (e.g., SI nucleases (Hyrup B. (1996) supra)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. et al.
  • PNAs can be modified, (e.g., to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.
  • PNA-DNA chimeras can be generated which may combine the advantageous properties of PNA and DNA.
  • DNA recognition enzymes e.g., RNAse H and DNA polymerases
  • PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) supra).
  • the synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) supra and Finn P.J. et al. (1996) Nucleic Acids Res. 24 (17): 3357-63.
  • a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. et al. (1989) Nucleic Acid Res. 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) suprd). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. et al. (1975) Bioorganic Med. Chem. Lett. 5: 1119-11124).
  • modified nucleoside analogs e.g., 5
  • the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. US 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. W088/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134, published April 25, 1988).
  • peptides e.g., for targeting host cell receptors in vivo
  • agents facilitating transport across the cell membrane see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. US 86:6553-6556; Lemaitre et al.
  • oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al. (1988) BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon (1988) Pharm. Res. 5:539-549).
  • the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).
  • STMST molecules of the present invention are in the screening for STMST ligands (e.g., surrogate ligands) and/or STMST modulators, it is intended that the following are also within the scope of the present invention: isolated nucleic acids which encode and STMST ligands or STMST modulators, probes and/or primers useful for identifying STMST ligands or STMST modulators based on the sequences of nucleic acids which encode and STMST ligands or STMST modulators, isolated nucleic acid molecules which are complementary or antisense to the sequences of nucleic acids which encode and STMST ligands or STMST modulators, isolated nucleic acid molecules which are at least about 60-65%), preferably at least about 70-75%), more preferable at least about 80-85%), and even more preferably at least about 90-95% or more homologous to the sequences of nucleic acids which encode and STMST ligands or STM
  • One aspect ofthe invention pertains to isolated BDSF proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti -BDSF antibodies.
  • Another aspect ofthe invention pertains to isolated STMST proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-STMST antibodies.
  • native proteins e.g., BDSF or STMST proteins
  • proteins e.g., BDSF or STMST proteins
  • proteins are produced by recombinant DNA techniques.
  • a BDSF or STMST protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
  • an “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
  • the language “substantially free of cellular material” includes preparations of protein (e.g., BDSF or STMST proteins) in which the protein is separated from cellular components ofthe cells from which it is isolated or recombinantly produced.
  • the language "substantially free of cellular material” includes preparations of protein having less than about 30%) (by dry weight) of non-BDSF protein or non-STMST protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non- BDSF protein or non-STMST protein, still more preferably less than about 10%> of non- BDSF protein or non-STMST protein, and most preferably less than about 5%> non- BDSF protein or non-STMST protein.
  • non-BDSF protein or non-STMST protein also referred to herein as a "contaminating protein”
  • culture medium represents less than about 20%>, more preferably less than about 10%), and most preferably less than about 5% ofthe volume ofthe protein preparation.
  • the language “substantially free of chemical precursors or other chemicals” includes preparations of protein (e.g., BDSF or STMST proteins) in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis ofthe protein.
  • the language “substantially free of chemical precursors or other chemicals” includes preparations of protein having less than about 30% (by dry weight) of chemical precursors or non-BDSF chemicals (or non- BDSF chemicals), more preferably less than about 20% chemical precursors or non- BDSF chemicals (or non-BDSF chemicals), still more preferably less than about 10%> chemical precursors or non-BDSF chemicals (or non-BDSF chemicals), and most preferably less than about 5%> chemical precursors or non-BDSF chemicals (or non- BDSF chemicals).
  • the BDSF protein has an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:7.
  • the BDSF protein is substantially homologous to SEQ ID NO:2 or SEQ ID NO:7, and retains the functional activity ofthe protein of SEQ ID NO:2 or SEQ ID NO:7, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above.
  • the BDSF protein is a protein which comprises an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:7 and retains the functional activity of the BDSF proteins of SEQ ID NO:2 or SEQ ID NO:7.
  • the protein is at least about 35-40% homologous to SEQ ID NO:2 or SEQ ID NO:7, more preferably at least about 40-45% homologous to SEQ ID NO:2 or SEQ ID NO:7, even more preferably at least about 45-50%> homologous to SEQ ID NO:2 or SEQ ID NO:7, and even more preferably at least about 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, or 90-95% or more homologous to SEQ ID NO:2 or SEQ ID NO:7.
  • the sequences are aligned for optimal comparison pu ⁇ oses (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence and non-homologous sequences can be disregarded for comparison pu ⁇ oses).
  • the length of a reference sequence aligned for comparison pu ⁇ oses is at least 30%>, preferably at least 40%, more preferably at least 50%>, even more preferably at least 60%>, and even more preferably at least 70%>, 80%>, or 90%> ofthe length ofthe reference sequence (e.g., when aligning a second sequence to the BDSF amino acid sequence of SEQ ID NO:2 or SEQ ID NO:7 having 293 amino acid residues, at least 88, preferably at least 117, more preferably at least 147, even more preferably at least 176, and even more preferably at least 205, 234 or 264 amino acid residues are aligned).
  • amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared.
  • a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology” is equivalent to amino acid or nucleic acid "identity").
  • the comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithim.
  • a preferred, non- limiting example of a mathematical algorithim utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77.
  • Such an algorithm is inco ⁇ orated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al (1990) J. Mol. Biol. 215:403-10.
  • Gapped BLAST can be utilized as described in Altschul et al, (1997) Nucleic Acids Research 25(17):3389-3402.
  • the default parameters ofthe respective programs e.g., XBLAST and NBLAST
  • XBLAST and NBLAST can be used. See http://www.ncbi.nlm.nih.gov.
  • Another preferred, non-limiting example of a mathematical algorithim utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989).
  • Biologically active portions of a BDSF protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence ofthe BDSF protein, e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:7, which include less amino acids than the full length BDSF proteins, and exhibit at least one activity of a BDSF protein.
  • biologically active portions comprise a domain or motif with at least one activity ofthe BDSF protein.
  • a biologically active portion of a BDSF protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.
  • a biologically active portion of a BDSF protein comprises an Ig-like domain. In another embodiment, a biologically active portion of a BDSF protein comprises at least an Ig-like domain and a signal sequence.
  • a preferred biologically active portion of a BDSF protein ofthe present invention may contain at least one ofthe above-identified structural domains.
  • a more preferred biologically active portion of a BDSF protein may contain at least two ofthe above-identified structural domains.
  • other biologically active portions, in which other regions ofthe protein are deleted, can be prepared by recombinant techniques and evaluated for one or more ofthe functional activities of a native BDSF protein.
  • the STMST protein has an amino acid sequence shown in SEQ ID NO: 15.
  • the STMST protein is substantially homologous to SEQ ID NO: 15, and retains the functional activity ofthe protein of SEQ ID NO: 15, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above.
  • the STMST protein is a protein which comprises an amino acid sequence at least about 75% homologous to the amino acid sequence of SEQ ID NO: 15 and retains the functional activity ofthe STMST proteins of SEQ ID NO: 15, respectively.
  • the protein is at least about 75-80%% homologous to SEQ ID NO: 15, more preferably at least about 80-85%> homologous to SEQ ID NO: 15, even more preferably at least about 85-90% homologous to SEQ ID NO: 15, and most preferably at least about 90-95% or more homologous to SEQ ID NO:15.
  • the STMST protein has an amino acid sequence shown in SEQ ID NO: 18.
  • the STMST protein is substantially homologous to SEQ ID NO: 18, and retains the functional activity ofthe protein of SEQ ID NO: 18, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above.
  • the STMST protein is a protein which comprises an amino acid sequence at least about 65% homologous to the amino acid sequence of SEQ ID NO: 15 and retains the functional activity ofthe STMST proteins of SEQ ID NO: 15, respectively.
  • the protein is at least about 65-70%>%> homologous to SEQ ID NO: 15, more preferably at least about 70-75%) homologous to SEQ ID NO: 15, even more preferably at least about 75-80%) homologous to SEQ ID NO: 15, and most preferably at least about 80-85%,85-90%, or 90-95% homologous to SEQ ID NO: 15.
  • Biologically active portions of an STMST protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence ofthe STMST protein, e.g., the amino acid sequence shown in SEQ ID NO: 15 or the amino acid sequence shown in SEQ ID NO: 18, which include less amino acids than the full length STMST proteins, and exhibit at least one activity of an STMST protein.
  • biologically active portions comprise a domain or motif with at least one activity ofthe STMST protein.
  • a biologically active portion of an STMST protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.
  • a biologically active portion of an STMST protein comprises at least a transmembrane domain. In another embodiment, a biologically active portion of an STMST protein comprises at least one 7 transmembrane receptor profile. In another embodiment, a biologically active portion of an STMST protein comprises at least a spectrin a-chain, repeated domain profile. In another embodiment a biologically active portion of an STMST protein comprises at least a 7 transmembrane receptor profile and a spectrin ⁇ -chain profile.
  • a preferred biologically active portion of an STMST protein ofthe present invention may contain at least one ofthe above-identified structural domains and/or profiles.
  • a more preferred biologically active portion of an STMST protein may contain at least two ofthe above-identified structural domains and/or profiles.
  • other biologically active portions, in which other regions of the protein are deleted can be prepared by recombinant techniques and evaluated for one or more ofthe functional activities of a native STMST protein.
  • a "chimeric protein” or “fusion protein” comprises a BDSF or STMST polypeptide operatively linked to a non-BDSF polypeptide or non-STMST polypeptide, respectively.
  • a "BDSF polypeptide” refers to a polypeptide having an amino acid sequence corresponding to BDSF
  • a “non-BDSF polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the BDSF protein, e.g., a protein which is different from the BDSF protein and which is derived from the same or a different organism.
  • a "STMST polypeptide” refers to a polypeptide having an amino acid sequence corresponding to STMST
  • a “non-STMST polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the STMST protein, e.g., a protein which is different from the STMST protein and which is derived from the same or a different organism.
  • the BDSF or STMST polypeptide can correspond to all or a portion of a BDSF or STMST protein, respectively.
  • a fusion protein comprises at least one biologically active portion of a BDSF or STMST protein.
  • a fusion protein comprises at least two biologically active portions of a BDSF or STMST protein.
  • the term "operatively linked" is intended to indicate that the BDSF or STMST polypeptide and the non-BDSF polypeptide or non-STMST polypeptide are fused in-frame to each other.
  • the non-BDSF polypeptide or non-STMST polypeptide can be fused to the N-terminus or C-terminus ofthe BDSF polypeptide or STMST polypeptide, respectively.
  • the fusion protein is a GST-BDSF fusion protein in which the BDSF sequences are fused to the C-terminus ofthe GST sequences.
  • the fusion protein can facilitate the purification of recombinant BDSF.
  • the fusion protein is a GST-STMST fusion protein in which the STMST sequences are fused to the C-terminus ofthe GST sequences.
  • Such fusion proteins can facilitate the purification of recombinant STMST.
  • the fusion protein is a BDSF protein containing a heterologous signal sequence at its N-terminus.
  • the native BDSF signal sequence i.e, about amino acids 1 to 25 of SEQ ID NO:2 or about amino acids 1 to 24 of SEQ ID NO: 7 can be removed and replaced with a signal sequence from another protein.
  • the fusion protein is an STMST protein containing a heterologous signal sequence at its N-terminus.
  • expression and/or secretion of BDSF can be increased through use of a heterologous signal sequence.
  • the fusion proteins ofthe invention can be inco ⁇ orated into pharmaceutical compositions and administered to a subject in vivo.
  • the fusion proteins can be used to affect the bioavailability of a BDSF or STMST target molecule.
  • Use of BDSF fusion proteins may be useful therapeutically for the treatment of proliferative disorders (e.g., cancer).
  • Use of STMST fusion proteins may be useful therapeutically for the treatment of respiratory disorders (e.g., asthma).
  • the fusion proteins ofthe invention can be used as immunogens to produce antibodies in a subject, to purify ligands and/or target molecules and in screening assays to identify molecules which inhibit the interaction of BDSF with a BDSF target molecule or the interaction of STMST with an STMST ligand.
  • a chimeric or fusion protein ofthe invention is produced by standard recombinant DNA techniques.
  • DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for Hgation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al. John Wiley & Sons: 1992).
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence
  • many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
  • a BDSF-encoding nucleic acid or STMST-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the BDSF protein or STMST protein, respectively.
  • the present invention also pertains to variants ofthe BDSF proteins which function as either BDSF agonists (mimetics) or as BDSF antagonists and to variants of the STMST proteins which function as either STMST agonists (mimetics) or as STMST antagonists.
  • Variants ofthe BDSF and BDSF proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of a BDSF or STMST protein, respectively.
  • An agonist ofthe BDSF or STMST proteins can retain substantially the same, or a subset, ofthe biological activities ofthe naturally occurring form of a BDSF protein or STMST protein, respectively.
  • An antagonist can inhibit one or more ofthe activities of the naturally occurring form ofthe protein by, for example, competitively inhibiting the activity ofthe BDSF or STMST protein.
  • specific biological effects can be elicited by treatment with a variant of limited function.
  • treatment of a subject with a variant having a subset ofthe biological activities ofthe naturally occurring form ofthe protein has fewer side effects in a subject relative to treatment with the naturally occurring form ofthe protein.
  • variants of a BDSF or STMST protein which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a BDSF or STMST protein for agonist or antagonist activity.
  • a variegated library of BDSF or STMST variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
  • a variegated library can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential BDSF or STMST sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of BDSF or STMST sequences therein.
  • libraries of fragments of a BDSF or STMST protein coding sequence can be used to generate a variegated population of fragments for screening and subsequent selection of protein variants.
  • a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector.
  • an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of a BDSF or STMST protein.
  • Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify BDSF or STMST variants (Arkin and Yourvan (1992) PNAS 59:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
  • cell based assays can be exploited to analyze a variegated library.
  • a library of expression vectors can be transfected into a cell line which ordinarily synthesizes and secretes BDSF or STMST.
  • the transfected cells are then cultured such that BDSF and a particular mutant BDSF (or STMST and a particular mutant) are secreted and the effect of expression ofthe mutant on BDSF or STMST activity in cell supernatants can be detected, e.g., by any of a number of enzymatic or binding assays.
  • Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of BDSF or STMST activity, and the individual clones further characterized.
  • an isolated BDSF or STMST protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind BDSF or STMST using standard techniques for polyclonal and monoclonal antibody preparation.
  • a full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments or use as immunogens.
  • an antigenic peptide of BDSF comprises at least 8 amino acid residues ofthe amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:7 and encompasses an epitope of BDSF such that an antibody raised against the peptide forms a specific immune complex with BDSF.
  • an antigenic peptide of STMST comprises at least 8 amino acid residues ofthe amino acid sequence shown in SEQ ID NO: 15 and encompasses an epitope of STMST such that an antibody raised against the peptide forms a specific immune complex with STMST.
  • the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.
  • Preferred epitopes encompassed by the antigenic peptide are regions of BDSF that are located on the surface ofthe protein, e.g., hydrophilic regions.
  • a BDSF or STMST immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen.
  • An appropriate immunogenic preparation can contain, for example, recombinantly expressed protein or a chemically synthesized polypeptide.
  • the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent.
  • Immunization of a suitable subject with an immunogenic BDSF preparation induces a polyclonal anti-BDSF antibody response.
  • immunization of a suitable subject with an immunogenic STMST preparation induces a polyclonal anti-STMST antibody response.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as BDSF or STMST.
  • immunologically active portions of immunoglobulin molecules include F(ab) and F(ab') 2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
  • the invention provides polyclonal and monoclonal antibodies that bind BDSF or STMST.
  • monoclonal antibody or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of BDSF or STMST.
  • a monoclonal antibody composition thus typically displays a single binding affinity for a particular BDSF protein with which it immunoreacts.
  • Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a BDSF or STMST immunogen.
  • the specific antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized BDSF or STMST.
  • ELISA enzyme linked immunosorbent assay
  • the antibody molecules can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.
  • protein A chromatography to obtain the IgG fraction.
  • antibody-producing cells when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol. 127:539-46; Brown et al. (1980) 7. Biol. Chem .255:4980-83; Ye et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al.
  • an immortal cell line typically a myeloma
  • lymphocytes typically splenocytes
  • STMST immunogen as described above
  • the culture supernatants ofthe resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds BDSF or STMST, respectively.
  • the immortal cell line e.g., a myeloma cell line
  • the immortal cell line is derived from the same mammalian species as the lymphocytes.
  • murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation ofthe present invention with an immortalized mouse cell line.
  • Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium").
  • HAT medium culture medium containing hypoxanthine, aminopterin and thymidine
  • Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g. , the P3-NS1/1- Ag4-1, P3-x63-Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC.
  • HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").
  • PEG polyethylene glycol
  • Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed).
  • Hybridoma cells producing a monoclonal antibody ofthe invention are detected by screening the hybridoma culture supernatants for antibodies that bind BDSF or STMST, e.g., using a standard ELISA assay.
  • a monoclonal anti-BDSF or anti-STMST antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with BDSF or STMST, respectively, to thereby isolate immunoglobulin library members that bind BDSF or STMST.
  • Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01 ; and the Stratagene SurfZAPTM Phage Display Kit, Catalog No. 240612).
  • examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT International Publication No. WO 92/18619; Dower et al PCT International Publication No. WO 91/17271; Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al PCT
  • recombinant antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant D ⁇ A techniques, are within the scope ofthe invention.
  • Such chimeric and humanized monoclonal antibodies can be produced by recombinant D ⁇ A techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al.
  • An anti-BDSF or anti-STMST antibody e.g., monoclonal antibody
  • An anti-BDSF or anti-STMST antibody can facilitate the purification of natural BDSF or STMST from cells and of recombinantly produced BDSF or STMST expressed in host cells.
  • an anti-BDSF or anti-STMST antibody can be used to detect BDSF protein or STMST (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression ofthe BDSF or STMST protein.
  • Anti-BDSF or anti-STMST antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
  • Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 I,
  • vectors preferably expression vectors, containing a nucleic acid encoding a BDSF or STMST protein (or a portion thereof).
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector is another type of vector, wherein additional DNA segments can be ligated into the viral genome.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g., non-episomal mammalian vectors
  • Other vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked.
  • Such vectors are referred to herein as "expression vectors".
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector can be used interchangeably as the plasmid is the most commonly used form of vector.
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
  • the recombinant expression vectors ofthe invention comprise a nucleic acid of the invention in a form suitable for expression ofthe nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis ofthe host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed.
  • "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression ofthe nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
  • regulatory sequence is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression ofthe nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design ofthe expression vector can depend on such factors as the choice ofthe host cell to be transformed, the level of expression of protein desired, etc.
  • the expression vectors ofthe invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., BDSF proteins, mutant forms of BDSF proteins, STMST proteins, mutant forms of STMST proteins, fusion proteins, etc.).
  • proteins or peptides including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., BDSF proteins, mutant forms of BDSF proteins, STMST proteins, mutant forms of STMST proteins, fusion proteins, etc.).
  • the recombinant expression vectors ofthe invention can be designed for expression of BDSF or STMST proteins in prokaryotic or eukaryotic cells.
  • BDSF or STMST proteins can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus ofthe recombinant protein.
  • Such fusion vectors typically serve three pu ⁇ oses: 1) to increase expression of recombinant protein; 2) to increase the solubility ofthe recombinant protein; and 3) to aid in the purification ofthe recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction ofthe fusion moiety and the recombinant protein to enable separation ofthe recombinant protein from the fusion moiety subsequent to purification ofthe fusion protein.
  • enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S.
  • GST glutathione S-transferase
  • Purified fusion proteins can be utilized in BDSF or STMST activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for BDSF or STMST proteins, for example.
  • a BDSF or STMST fusion protein expressed in a retroviral expression vector ofthe present invention can be utilized to infect bone marrow cells which are subsequently transplanted into irradiated recipients. The pathology ofthe subject recipient is then examined after sufficient time has passed (e.g six (6) weeks).
  • Suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al, (1988) Gene 69:301-315) and pET 1 Id (Studier et al, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid tip-lac fusion promoter.
  • Target gene expression from the pET l id vector relies on transcription from a T7 gnlO-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident prophage harboring a T7 gnl gene under the transcriptional control ofthe lacUV 5 promoter.
  • the BDSF or STMST expression vector is a yeast expression vector.
  • yeast expression vectors for expression in yeast S. cerivisae include pYepSecl (Baldari, et al, (1987) Embo J 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al, (1987) Gene 54:113-123), pYES2 (Invitrogen Co ⁇ oration, San Diego, CA), and picZ (InVitrogen Co ⁇ , San Diego, CA).
  • BDSF or STMST proteins can be expressed in insect cells using baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol. Cell Biol 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
  • a nucleic acid ofthe invention is expressed in mammalian cells using a mammalian expression vector.
  • mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBOJ 6:187-195).
  • the expression vector's control functions are often provided by viral regulatory elements.
  • promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, ⁇ Y, 1989.
  • the recombinant mammalian expression vector is capable of directing expression ofthe nucleic acid preferentially in a particular cell type (e.g. , tissue-specific regulatory elements are used to express the nucleic acid).
  • tissue-specific regulatory elements are known in the art. ⁇ on-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J.
  • promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the ⁇ -fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
  • the invention further provides a recombinant expression vector comprising a DNA molecule ofthe invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription ofthe DNA molecule) of an RNA molecule which is antisense to BDSF or STMST mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression ofthe antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • a high efficiency regulatory region the activity of which can be determined by the cell type into which the vector is introduced.
  • Another aspect ofthe invention pertains to host cells into which a recombinant expression vector ofthe invention has been introduced.
  • host cell and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope ofthe term as used herein.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • a BDSF or STMST protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).
  • bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells).
  • CHO Chinese hamster ovary cells
  • COS cells Chinese hamster ovary cells
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and transfection are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.
  • a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a BDSF or STMST protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have inco ⁇ orated the selectable marker gene will survive, while the other cells die).
  • a host cell ofthe invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a BDSF or STMST protein.
  • the invention further provides methods for producing a BDSF or STMST protein using the host cells ofthe invention.
  • the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a BDSF or STMST protein has been introduced) in a suitable medium such that a BDSF or STMST protein is produced.
  • the method further comprises isolating a BDSF or STMST protein from the medium or the host cell.
  • a host cell ofthe invention can also be used to produce nonhuman transgenic animals.
  • a host cell ofthe invention is a fertilized oocyte or an embryonic stem cell into which BDSF-coding sequences or STMST- coding sequences have been introduced.
  • Such host cells can then be used to create non- human transgenic animals in which exogenous BDSF or STMST sequences have been introduced into their genome or homologous recombinant animals in which endogenous BDSF or STMST sequences have been altered, respectively.
  • Such animals are useful for studying the function and/or activity of a BDSF or STMST and for identifying and/or evaluating modulators of BDSF or STMST activity.
  • a "transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more ofthe cells ofthe animal includes a transgene.
  • Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc.
  • a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome ofthe mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues ofthe transgenic animal.
  • a "homologous recombinant animal” is a non- human animal, preferably a mammal, more preferably a mouse, in which an endogenous BDSF or STMST gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell ofthe animal, e.g., an embryonic cell ofthe animal, prior to development ofthe animal.
  • a transgenic animal ofthe invention can be created by introducing a BDSF- or STMST-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • the BDSF cDNA sequence of SEQ ID NO:l or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number 98756 can be introduced as a transgene into the genome of a non- human animal.
  • the STMST cDNA sequence of SEQ ID NO: 14, SEQ ID NO: 17, the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number or the nucleotide sequence ofthe DNA insert ofthe plasmid deposited with ATCC as Accession Number can be introduced as a transgene into the genome of a non-human animal.
  • a nonhuman homologue of a human BDSF gene or STMST gene such as a mouse BDSF or STMST gene, can be used as a transgene.
  • a BDSF or STMST gene homologue can be isolated based on hybridization to a BDSF or STMST cDNA sequences and used as a transgene.
  • Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression ofthe transgene.
  • a tissue-specific regulatory sequence(s) can be operably linked to a BDSF or STMST transgene to direct expression of a BDSF or STMST protein to particular cells.
  • transgenic founder animal can be identified based upon the presence of a BDSF or STMST transgene in its genome and/or expression of BDSF or STMST mRNA in tissues or cells ofthe animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a BDSF or STMST protein can further be bred to other transgenic animals carrying other transgenes.
  • a vector is prepared which contains at least a portion of a BDSF or STMST gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the BDSF or STMST gene.
  • the BDSF or STMST gene can be a human gene (e.g. , the cDNA of SEQ ID NO: 1 or the cDNA sequence of SEQ ID NO: 14 or SEQ ID NO: 17), but more preferably, is a non-human homologue of a human BDSF or STMST gene such as a murine BDSF or STMST gene.
  • the mouse BDSF gene of SEQ ID NO:6 can be used to construct a homologous recombination vector suitable for altering an endogenous BDSF gene in the mouse genome.
  • the vector is designed such that, upon homologous recombination, the endogenous BDSF or STMST gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).
  • the vector can be designed such that, upon homologous recombination, the endogenous BDSF or STMST gene is mutated or otherwise altered but still encodes functional protein (e.g. , the upstream regulatory region can be altered to thereby alter the expression ofthe endogenous BDSF or STMST protein).
  • the altered portion ofthe BDSF or STMST gene is flanked at its 5' and 3' ends by additional nucleic acid sequence ofthe BDSF or STMST gene to allow for homologous recombination to occur between the exogenous BDSF or STMST gene carried by the vector and an endogenous BDSF or STMST gene in an embryonic stem cell.
  • the additional flanking BDSF or STMST nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene.
  • flanking DNA both at the 5' and 3' ends
  • flanking DNA are included in the vector (see e.g., Thomas, K.R. and Capecchi, M.
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced BDSF or STMST gene has homologously recombined with the endogenous BDSF or STMST gene are selected (see e.g., Li, E. et al (1992) Cell 69:915).
  • the selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E.J.
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
  • Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells ofthe animal contain the homologously recombined DNA by germline transmission ofthe transgene.
  • Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al. ; WO 91/01140 by Smithies et al. ; WO 92/0968 by Zijlstra et al. ; and WO 93/04169 by Berns et al.
  • transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression ofthe transgene.
  • a system is the cre/loxP recombinase system of bacteriophage PI .
  • cre/loxP recombinase system of bacteriophage PI .
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251 :1351-1355.
  • a cre/loxP recombinase system is used to regulate expression ofthe transgene
  • animals containing transgenes encoding both the Cre recombinase and a selected protein are required.
  • Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
  • Clones ofthe non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al (1997) Nature 385:810- 813.
  • a cell e.g., a somatic cell
  • the quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal ofthe same species from which the quiescent cell is isolated.
  • the recontructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal.
  • the offspring borne of this female foster animal will be a clone ofthe animal from which the cell, e.g., the somatic cell, is isolated.
  • compositions suitable for administration can be inco ⁇ orated into pharmaceutical compositions suitable for administration.
  • Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and abso ⁇ tion delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be inco ⁇ orated into the compositions.
  • a pharmaceutical composition ofthe invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance ofthe required particle size in the case of dispersion and by the use of surfactants.
  • Prevention ofthe action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged abso ⁇ tion ofthe injectable compositions can be brought about by including in the composition an agent which delays abso ⁇ tion, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by inco ⁇ orating the active compound (e.g., a BDSF protein, anti-BDSF antibody, STMST protein or anti-STMST antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • the active compound e.g., a BDSF protein, anti-BDSF antibody, STMST protein or anti-STMST antibody
  • dispersions are prepared by inco ⁇ orating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder ofthe active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the pu ⁇ ose of oral therapeutic administration, the active compound can be inco ⁇ orated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part ofthe composition.
  • the tablets, pills, capsules, troches and the like can contain any ofthe following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Co ⁇ oration and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms ofthe invention are dictated by and directly dependent on the unique characteristics ofthe active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50%> ofthe population) and the ED50 (the dose therapeutically effective in 50% ofthe population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50 ED50.
  • Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies 5 preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a o circulating plasma concentration range that includes the IC50 (/. e. , the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • the nucleic acid molecules ofthe invention can be inserted into vectors and used as gene therapy vectors.
  • Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) PNAS 91:3054-3057).
  • the pharmaceutical preparation ofthe gene therapy vector can include the gene therapy 0 vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
  • the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
  • the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • nucleic acid molecules, proteins, protein homologues, and antibodies 0 described herein can be used in one or more ofthe following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic).
  • a BDSF protein ofthe invention has one or more ofthe following activities: (i) interaction of a BDSF protein in the extracellular milieu with a non-BDSF protein molecule on the surface ofthe same cell which secreted the BDSF protein molecule; (ii) interaction of a BDSF protein in the extracellular milieu with a non-BDSF protein molecule on the surface of a different cell from that which secreted the BDSF protein molecule; (iii) complex formation between a BDSF protein and a BDSF receptor; (iv) complex formation between a BDSF protein and non-BDSF receptor; and (v) interaction of a BDSF protein with a second protein in the extracellular milieu, and can thus be used in, for example, (1) modulation of cellular signal transduction, either in vitro or in vivo; (2) modulation of proteimprotein interaction, either in vitro or in vivo; (3) regulation of cellular proliferation; or (4) regulation of cellular differentiation.
  • an STMST protein ofthe invention has one or more ofthe following activities: (i) interaction of an STMST protein with soluble STMST ligand; (ii) interaction of an STMST protein with a membrane-bound non-STMST protein; (iii) interaction of an STMST protein with an intracellular protein (e.g., an intracellular enzyme or signal transduction molecule); and (iv) indirect interaction of an STMST protein with an intracellular protein (e.g.
  • a downstream signal transduction molecule can thus be used in, for example, (1) modulation of cellular signal transduction, either in vitro or in vivo; (2) regulation of gene transcription in a cell expressing an STMST protein; (3) regulation of gene transcription in a cell expressing an STMST protein, wherein said cell is involved inflammation; (4) regulation of cellular proliferation; (5) regulation of cellular differentiation; (6) regulation of develpoment; (7) regulation of cell death; (8) regulation of inflammation; and (9) regulation of respiratory cell function.
  • the isolated nucleic acid molecules ofthe invention can be used, for example, to express BDSF or STMST protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect BDSF or STMST mRNA (e.g., in a biological sample) or a genetic alteration in a BDSF or STMST gene, and to modulate BDSF or STMST activity, as described further below.
  • the BDSF or STMST proteins can be used to treat disorders characterized by insufficient or excessive production of a BDSF, STMST, BDSF target molecule, or STMST target molecule.
  • the BDSF or STMST proteins can be used to screen for naturally occurring BDSF or STMST target molecules, to screen for drugs or compounds which modulate BDSF or STMST activity, as well as to treat disorders characterized by insufficient or excessive production of BDSF or STMST protein or production of BDSF or STMST protein forms which have decreased or aberrant activity compared to BDSF or STMST wild type protein.
  • the anti-BDSF antibodies or anti-STMST antibodies ofthe invention can be used to detect and isolate BDSF or STMST proteins, regulate the bioavailability of BDSF or STMST proteins, and modulate BDSF or STMST activity.
  • one embodiment ofthe present invention involves a method of use (e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a molecule ofthe present invention (e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator) is used, for example, to diagnose, prognose and/or treat a disease and/or condition in which any ofthe aforementioned activities is indicated.
  • a molecule ofthe present invention e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator
  • the present invention involves a method of use (e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a molecule ofthe present invention (e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator) is used, for example, for the diagnosis, prognosis, and/or treatment of subjects, preferably a human subject, in which any ofthe aforementioned activities is pathologically perturbed.
  • a method of use e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment
  • a molecule ofthe present invention e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator
  • the methods of use involve administering to a subject, preferably a human subject, a molecule ofthe present invention (e.g., a BDSF protein, BDSF nucleic acid, a BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator) for the diagnosis, prognosis, and/or therapeutic treatment.
  • a molecule ofthe present invention e.g., a BDSF protein, BDSF nucleic acid, a BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator
  • the methods of use involve administering to a human subject a molecule ofthe present invention (e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator).
  • a molecule ofthe present invention e.g., a BDSF protein, BDSF nucleic acid, BDSF modulator, STMST protein, STMST nucleic acid, STMST ligand or STMST modulator.
  • the invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to BDSF or STMST proteins, have a stimulatory or inhibitory effect on, for example, BDSF or STMST expression or BDSF or STMST activity, or have a stimulatory or inhibitory effect on, for example, the activity of an BDSF or STMST target molecule.
  • modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to BDSF or STMST proteins, have a stimulatory or inhibitory effect on, for example, BDSF or STMST expression or BDSF or STMST activity, or have a stimulatory or inhibitory effect on, for example, the activity of an BDSF or STMST target molecule.
  • the invention provides assays for screening candidate or test compounds which are target molecules of a BDSF or STMST protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a BDSF or STMST protein or polypeptide or biologically active portion thereof.
  • the test compounds ofthe present invention can be obtained using any ofthe numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des. 12:145).
  • an assay is a cell-based assay in which a cell which expresses a BDSF protein or biologically active portion thereof is contacted with a test compound and the ability ofthe test compound to modulate BDSF activity determined. Determining the ability ofthe test compound to modulate BDSF activity can be accomplished by monitoring the bioactivity ofthe BDSF protein or biologically active portion thereof.
  • the cell for example, can be of mammalian origin or a yeast cell.
  • Determining the ability ofthe test compound to modulate BDSF activity can be accomplished, for example, by coupling the BDSF protein or biologically active portion thereof with a radioisotope or enzymatic label such that binding ofthe BDSF protein or biologically active portion thereof to its cognate target molecule can be determined by detecting the labeled BDSF protein or biologically active portion thereof in a complex.
  • compounds e.g., BDSF protein or biologically active portion thereof
  • compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
  • a microphysiometer can be used to detect the interaction of a compound with its cognate target molecule without the labeling of either the compound or the receptor. McConnell, H. M. et al. (1992) Science 257:1906-1912.
  • a "microphysiometer” e.g., Cytosensor
  • LAPS light-addressable potentiometric sensor
  • the assay comprises contacting a cell which expresses a BDSF protein or biologically active portion thereof, with a target molecule to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to modulate the activity ofthe BDSF protein or biologically active portion thereof, wherein determining the ability ofthe test compound to modulate the activity ofthe BDSF protein or biologically active portion thereof, comprises determining the ability ofthe test compound to modulate a biological activity ofthe BDSF expressing cell (e.g. , determining the ability ofthe test compound to modulate signal transduction or protei protein interactions).
  • the assay comprises contacting a cell which is responsive to a BDSF protein or biologically active portion thereof, with a BDSF protein or biologically-active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to modulate the activity ofthe BDSF protein or biologically active portion thereof, wherein determining the ability ofthe test compound to modulate the activity ofthe BDSF protein or biologically active portion thereof comprises determining the ability ofthe test compound to modulate a biological activity ofthe BDSF-responsive cell (e.g., determining the ability ofthe test compound to modulate signal transduction or proteimprotein interactions).
  • an assay is a cell-based assay comprising contacting a cell expressing a BDSF target molecule with a test compound and determining the ability ofthe test compound to modulate (e.g. stimulate or inhibit) the activity ofthe BDSF target molecule. Determining the ability ofthe test compound to modulate the activity of a BDSF target molecule can be accomplished, for example, by determining the ability ofthe BDSF protein to bind to or interact with the BDSF target molecule. Determining the ability ofthe BDSF protein to bind to or interact with a BDSF target molecule can be accomplished by one ofthe methods described above for determining direct binding.
  • determining the ability ofthe BDSF protein to bind to or interact with a BDSF target molecule can be accomplished by determining the activity ofthe target molecule.
  • the activity ofthe target molecule can be determined by detecting induction of a cellular second messenger ofthe target (i.e.
  • a reporter gene comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase
  • a target-regulated cellular response for example, signal transduction or ⁇ rotein:protein interactions.
  • an assay is a cell-based assay in which a cell which expresses an STMST protein on the cell surface is contacted with a test compound and the ability ofthe test compound to bind to the STMST protein determined.
  • the cell for example, can be of mammalian origin or a yeast cell. Determining the ability ofthe test compound to bind to an STMST protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding ofthe test compound to the STMST protein can be determined by detecting the labeled compound in a complex.
  • test compounds can be labeled with 125 I, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting.
  • test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
  • a microphysiometer can be used to detect the interaction of a test compound with an STMST protein without the labeling of either the test compound or the receptor, as described above.
  • the assay comprises contacting a cell which expresses an STMST protein or biologically active portion thereof, on the cell surface with an STMST ligand, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with the STMST protein or biologically active portion thereof, wherein determining the ability of the test compound to interact with the STMST protein or biologically active portion thereof, comprises determining the ability ofthe test compound to preferentially bind to the STMST protein or biologically active portion thereof, as compared to the ability of the STMST ligand to bind to the STMST protein or biologically active portion thereof.
  • Determining the ability ofthe STMST ligand or STMST modulator to bind to or interact with an STMST protein or biologically active portion thereof can be accomplished by one ofthe methods described above for determining direct binding.
  • determining the ability ofthe STMST ligand or modulator to bind to or interact with an STMST protein or biologically active portion thereof can be accomplished by determining the activity of an STMST protein or of a downstream STMST target molecule.
  • the target molecule can be a cellular second messenger, and the activity ofthe target molecule can be determined by detecting induction of of the target (i.e.
  • a reporter gene comprising an STMST-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase
  • a cellular response for example, a proliferative response or an inflammatory response.
  • the present invention involves a method of identifying a compound which modulates the activity of an STMST protein, comprising contacting a cell which expresses an STMST protein with a test compound, determining the ability ofthe test compound to modulate the activity the STMST protein, and identifying the compound as a modulator of STMST activity.
  • the present invention involves a method of identifying a compound which modulates the activity of an STMST protein, comprising contacting a cell which expresses an STMST protein with a test compound, determining the ability ofthe test compound to modulate the activity of a downstream STMST target molecule, and identifying the compound as a modulator of STMST activity.
  • an assay ofthe present invention is a cell-free assay in which a BDSF or STMST protein or biologically active portion thereof is contacted with a test compound and the ability ofthe test compound to bind to the BDSF or STMST protein or biologically active portion thereof is determined. Binding ofthe test compound to the BDSF or STMST protein can be determined either directly or indirectly as described above.
  • the assay includes contacting the BDSF or STMST protein or biologically active portion thereof with a known compound which binds BDSF or STMST (e.g., a BDSF or STMST target molecule) to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with a BDSF or STMST protein, wherein determining the ability ofthe test compound to interact with a BDSF or STMST protein comprises determining the ability ofthe test compound to preferentially bind to BDSF or STMST or biologically active portion thereof as compared to the known compound.
  • a known compound which binds BDSF or STMST e.g., a BDSF or STMST target molecule
  • the assay is a cell-free assay in which a BDSF protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity ofthe BDSF protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a BDSF protein can be accomplished, for example, by determining the ability ofthe BDSF protein to bind to a BDSF target molecule by one ofthe methods described above for determining direct binding.
  • BDSF protein Determining the ability ofthe BDSF protein to bind to a BDSF target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA).
  • BIOA Biomolecular Interaction Analysis
  • BIA is a technology for studying biospecific interactions in real time, without labeling any ofthe interactants (e.g., BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.
  • SPR surface plasmon resonance
  • determining the ability ofthe test compound to modulate the activity of a BDSF protein can be accomplished by determining the ability ofthe BDSF protein to further modulate the activity of a downstream effector (e.g., a growth factor mediated signal transduction pathway component) of a BDSF target molecule.
  • a downstream effector e.g., a growth factor mediated signal transduction pathway component
  • the activity ofthe effector molecule on an appropriate target can be determined or the binding ofthe effector to an appropriate target can be determined as previously described.
  • the cell-free assay involves contacting a BDSF protein or biologically active portion thereof with a known compound which binds the BDSF protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with the BDSF protein, wherein determining the ability ofthe test compound to interact with the BDSF protein comprises determining the ability ofthe BDSF protein to preferentially bind to or modulate the activity of a BDSF target molecule.
  • an assay ofthe present invention is a cell-free assay in which an STMST protein or biologically active portion thereof is contacted with a test compound and the ability ofthe test compound to bind to the STMST protein or biologically active portion thereof is determined. Binding ofthe test compound to the STMST protein can be determined either directly or indirectly or using BIA as described above.
  • the assay includes contacting the STMST protein or biologically active portion thereof with a known ligand which binds STMST to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with an STMST protein, wherein determining the ability ofthe test compound to interact with an STMST protein comprises determining the ability ofthe test compound to preferentially bind to STMST or biologically active portion thereof as compared to the known ligand.
  • the assay is a cell-free assay in which an STMST protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity ofthe STMST protein or biologically active portion thereof is determined.
  • Determining the ability of the test compound to modulate the activity of an STMST protein can be accomplished, for example, by determining the ability ofthe STMST protein to modulate the activity of a downstream STMST target molecule by one ofthe methods described above for cell- based assays. For example, the catalytic/enzymatic activity ofthe target molecule on an appropriate substrate can be determined as previously described.
  • the cell-free assay involves contacting an STMST protein or biologically active portion thereof with a known ligand which binds the STMST protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with the STMST protein, wherein determining the ability ofthe test compound to interact with the STMST protein comprises determining the ability ofthe test compound to preferentially bind to or modulate the activity of an STMST target molecule, as compared to the known ligand.
  • the cell-free assays ofthe present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins (e.g. BDSF or STMST proteins or biologically active portions thereof or receptors to which BDSF targets bind or STMST proteins or biologically active portions thereof or STMST proteins).
  • isolated proteins e.g. BDSF or STMST proteins or biologically active portions thereof or receptors to which BDSF targets bind or STMST proteins or biologically active portions thereof or STMST proteins.
  • a membrane-bound form an isolated protein e.g., a cell surface receptor
  • non-ionic detergents such as n-oct
  • BDSF or STMST Binding of a test compound to a BDSF or STMST protein, or interaction of a BDSF or STMST protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes.
  • a fusion protein can be provided which adds a domain that allows one or both ofthe proteins to be bound to a matrix.
  • GST/ BDSF fusion proteins, GST/STMST fusion proteins or GST/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein, BDSF or STMST protein, and the mixture incubated under conditions conducive to complex formation (e.g. , at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of BDSF or STMST binding or activity determined using standard techniques.
  • BDSF protein BDSF protein.
  • STMST fusion protein, a BDSF target molecule or STMST target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
  • Biotinylated BDSF or STMST protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies reactive with BDSF protein, STMST proteins or target molecules but which do not interfere with binding ofthe BDSF or STMST protein to its target molecule can be derivatized to the wells ofthe plate, and unbound target or BDSF or STMST protein trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the BDSF protein, STMST protein or target molecules, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the BDSF protein, STMST protein or respective target molecule.
  • modulators of BDSF or STMST expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of BDSF or STMST mRNA or protein in the cell is determined. The level of expression of BDSF or STMST mRNA or protein in the presence ofthe candidate compound is compared to the level of expression of BDSF or STMST mRNA or protein in the absence ofthe candidate compound. The candidate compound can then be identified as a modulator of BDSF or STMST expression based on this comparison.
  • the candidate compound when expression of BDSF or STMST mRNA or protein is greater (statistically significantly greater) in the presence ofthe candidate compound than in its absence, the candidate compound is identified as a stimulator of BDSF or STMST mRNA or protein expression.
  • the candidate compound when expression of BDSF or STMST mRNA or protein is less (statistically significantly less) in the presence ofthe candidate compound than in its absence, the candidate compound is identified as an inhibitor of BDSF or STMST mRNA or protein expression.
  • the level of BDSF or STMST mRNA or protein expression in the cells can be determined by methods described herein for detecting BDSF or STMST mRNA or protein.
  • the BDSF or STMST proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) 7 Biol. Chem. 268: 12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al.
  • BDSF-binding proteins proteins which bind to or interact with BDSF or STMST
  • binding proteins are also likely to be involved in the propagation of signals by the BDSF proteins, STMST proteins or respective targets as, for example, downstream elements of a BDSF- or STMST-mediated signaling pathway.
  • BDSF-binding proteins or STMST-binding proteins are likely to be BDSF or STMST inhibitors.
  • the two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains.
  • the assay utilizes two different DNA constructs.
  • the gene that codes for a BDSF or STMST protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4).
  • a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey" or "sample”) is fused to a gene that codes for the activation domain ofthe known transcription factor.
  • the DNA-binding and activation domains ofthe transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression ofthe reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the BDSF or STMST protein.
  • a reporter gene e.g., LacZ
  • the present invention includes a compound or agent obtainable by a method comprising the steps of any one ofthe aformentioned screening assays (e.g., cell-based assays or cell-free assays).
  • the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a BDSF or STMST target molecule with a test compound and the determining the ability ofthe test compound to bind to, or modulate the activity of, the BDSF or STMST target molecule.
  • the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a BDSF or STMST target molecule with a BDSF or STMST protein or biologically-active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with, or modulate the activity of, the BDSF or STMST target molecule.
  • the invention includes a compound or agent obtainable by a method comprising contacting a BDSF or STMST protein or biologically active portion thereof with a test compound and determining the ability ofthe test compound to bind to, or modulate (e.g., stimulate or inhibit) the activity of, the BDSF or STMST protein or biologically active portion thereof.
  • the present invention included a compound or agent obtainable by a method comprising contacting a BDSF or STMST protein or biologically active portion thereof with a known compound which binds the BDSF or STMST protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability ofthe test compound to interact with, or modulate the activity ofthe BDSF or STMST protein.
  • an agent identified as described herein in an appropriate animal model.
  • an agent identified as described herein e.g., a BDSF or STMST modulating agent, an antisense BDSF or STMST nucleic acid molecule, a BDSF-specific or STMST-specific antibody, or a BDSF- or STMST-binding partner
  • an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
  • an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
  • this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.
  • the present inventon also pertains to uses of novel agents identified by the above-described screening assays for diagnoses, prognoses, and treatments as described herein. Accordingly, it is within the scope ofthe present invention to use such agents in the design, formulation, synthesis, manufacture, and/or production of a drug or pharmaceutical composition for use in diagnosis, prognosis, or treatment, as described herein.
  • the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition by reference to the structure and/or properties of a compound obtainable by one ofthe above-described screening assays.
  • a drug or pharmaceutical composition can be synthesized based on the structure and/or properties of a compound obtained by a method in which a cell which expresses a BDSF or STMST target molecule is contacted with a test compound and the ability ofthe test compound to bind to, or modulate the activity of, the BDSF or STMST target molecule is determined.
  • the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition based on the structure and/or properties of a compound obtainable by a method in which a BDSF or STMST protein or biologically active portion thereof is contacted with a test compound and the ability ofthe test compound to bind to, or modulate (e.g., stimulate or inhibit) the activity of, the BDSF or STMST protein or biologically active portion thereof is determined.
  • cDNA sequences identified herein can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
  • Chromosome Mapping Once the sequence (or a portion ofthe sequence) of a gene has been isolated, this sequence can be used to map the location ofthe gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments ofthe BDSF or STMST nucleotide sequences, described herein, can be used to map the location ofthe BDSF or STMST genes on a chromosome. The mapping ofthe BDSF or STMST sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
  • BDSF or STMST genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the BDSF or STMST nucleotide sequences. Computer analysis ofthe BDSF or STMST sequences can be used to predict primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the BDSF or STMST sequences will yield an amplified fragment.
  • Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. et al. (1983) Science 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.
  • PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the BDSF or STMST nucleotide sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a 9o, lp, or lv sequence to its chromosome include in situ hybridization (described in Fan, Y. et al.
  • FISH Fluorescence in situ hybridization
  • Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical such as colcemid that disrupts the mitotic spindle.
  • the chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually.
  • the FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1 ,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al, Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York 1988).
  • Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions ofthe genes actually are preferred for mapping pu ⁇ oses. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
  • a mutation is observed in some or all ofthe affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent ofthe particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymo ⁇ hisms. 2. Tissue Typing
  • the BDSF or STMST sequences ofthe present invention can also be used to identify individuals from minute biological samples.
  • the United States military, for example, is considering the use of restriction fragment length polymo ⁇ hism (RFLP) for identification of its personnel.
  • RFLP restriction fragment length polymo ⁇ hism
  • an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification.
  • This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult.
  • the sequences ofthe present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).
  • sequences ofthe present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome.
  • the BDSF or STMST nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends ofthe sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
  • Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences.
  • the sequences ofthe present invention can be used to obtain such identification sequences from individuals and from tissue.
  • the BDSF or STMST nucleotide sequences ofthe invention uniquely represent portions ofthe human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases.
  • Each ofthe sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification pu ⁇ oses.
  • SEQ ID NO:l SEQ ID NO:6, SEQ ID NO: 14 or SEQ ID NO: 17
  • SEQ ID NO: 13 SEQ ID NO:6, SEQ ID NO: 14 or SEQ ID NO: 17
  • a more appropriate number of primers for positive individual identification would be 500-2,000.
  • a panel of reagents from BDSF or STMST nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual.
  • positive identification ofthe individual, living or dead can be made from extremely small tissue samples.
  • DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a pe ⁇ etrator of a crime.
  • PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification ofthe origin ofthe biological sample.
  • sequences ofthe present invention can be used to provide polynucleotide reagents, e.g. , PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual).
  • an "identification marker” i.e. another DNA sequence that is unique to a particular individual.
  • actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments.
  • Sequences targeted to noncoding regions of SEQ ID NO: 1 are particularly appropriate for this use as greater numbers of polymo ⁇ hisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
  • polynucleotide reagents include the BDSF or STMST nucleotide sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:l, SEQ ID NO:6, SEQ ID NO:14 or SEQ ID NO:17 having a length of at least 20 bases, preferably at least 30 bases.
  • the BDSF or STMST nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such BDSF or STMST probes can be used to identify tissue by species and/or by organ type.
  • these reagents e.g., BDSF or STMST primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).
  • the present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) pu ⁇ oses to thereby treat an individual prophylactically.
  • diagnostic assays for determining BDSF or STMST protein and/or nucleic acid expression as well as BDSF or STMST activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant BDSF or STMST expression or activity.
  • a biological sample e.g., blood, serum, cells, tissue
  • the invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with BDSF or STMST protein, nucleic acid expression or activity. For example, mutations in a BDSF or STMST gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive pu ⁇ ose to thereby phophylactically treat an individual prior to the onset of a disorder characterized by or associated with BDSF or STMST protein, nucleic acid expression or activity.
  • Another aspect ofthe invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of BDSF in clinical trials.
  • agents e.g., drugs, compounds
  • An exemplary method for detecting the presence or absence of BDSF or STMST protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting BDSF or STMST protein or nucleic acid (e.g. , mRNA, genomic DNA) that encodes BDSF or STMST protein such that the presence of BDSF or STMST protein or nucleic acid is detected in the biological sample.
  • a preferred agent for detecting BDSF or STMST mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to BDSF or STMST mRNA or genomic DNA.
  • the nucleic acid probe can be, for example, a full-length BDSF nucleic acid, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to BDSF or STMST mRNA or genomic DNA.
  • Other suitable probes for use in the diagnostic assays ofthe invention are described herein.
  • a preferred agent for detecting BDSF or STMST protein is an antibody capable of binding to BDSF or STMST protein, preferably an antibody with a detectable label.
  • Antibodies can be polyclonal, or more preferably, monoclonal.
  • an intact antibody, or a fragment thereof can be used.
  • labeled with regard to the probe or antibody, is intended to encompass direct labeling ofthe probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling ofthe probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • biological sample is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method ofthe invention can be used to detect BDSF or STMST mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of BDSF or STMST mRNA include Northern hybridizations and in situ hybridizations.
  • In vitro techniques for detection of BDSF or STMST protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
  • In vitro techniques for detection of BDSF or STMST genomic DNA include Southern hybridizations.
  • in vivo techniques for detection of BDSF or STMST protein include introducing into a subject a labeled anti-BDSF or anti-STMST antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • the biological sample contains protein molecules from the test subject.
  • the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject.
  • a preferred biological sample is a serum sample isolated by conventional means from a subject.
  • the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting BDSF or STMST protein, mRNA, or genomic DNA, such that the presence of BDSF or STMST protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of BDSF or STMST protein, mRNA or genomic DNA in the control sample with the presence of BDSF or STMST protein, mRNA or genomic DNA in the test sample.
  • kits for detecting the presence of BDSF or STMST in a biological sample can comprise a labeled compound or agent capable of detecting BDSF or STMST protein or mRNA in a biological sample; means for determining the amount of BDSF or STMST in the sample; and means for comparing the amount of BDSF or STMST in the sample with a standard.
  • the compound or agent can be packaged in a suitable container.
  • the kit can further comprise instructions for using the kit to detect BDSF or STMST protein or nucleic acid.
  • the diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant BDSF or STMST expression or activity.
  • the assays described herein such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with BDSF protein, nucleic acid expression or activity such as a proliferative disorder (e.g., cancer).
  • the assays described herein, such as the preceding diagnostic assays or the following assays can be utilized to identify a subject having or at risk of developing a disorder associated with BDSF protein, nucleic acid expression or activity such as a proliferative disorder.
  • the prognostic assays can be utilized to identify a subject having or at risk for developing a differentiative disorder.
  • the present invention provides a method for identifying a disease or disorder associated with aberrant BDSF or STMST expression or activity in which a test sample is obtained from a subject and BDSF or STMST protein or nucleic acid (e.g, mRNA, genomic DNA) is detected, wherein the presence of BDSF or STMST protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant BDSF or STMST expression or activity.
  • a test sample refers to a biological sample obtained from a subject of interest.
  • a test sample can be a biological fluid (e.g. , serum), cell sample, or tissue.
  • the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant BDSF or STMST expression or activity.
  • an agent e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
  • an agent for a proliferative disorder e.g., cancer
  • a differentiative disorder or an immune disorder e.g., cancer
  • the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant BDSF or STMST expression or activity in which a test sample is obtained and BDSF or STMST protein or nucleic acid expression or activity is detected (e.g., wherein the abundance of BDSF or STMST protein or nucleic acid expression or activity is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant BDSF or STMST expression or activity.)
  • the methods ofthe invention can also be used to detect genetic alterations in a BDSF or STMST gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by an aberrant proliferative response.
  • the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a BDSF or STMST-protein, or the mis- expression ofthe BDSF or STMST gene.
  • such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a BDSF or STMST gene; 2) an addition of one or more nucleotides to a BDSF or STMST gene; 3) a substitution of one or more nucleotides of a BDSF or STMST gene, 4) a chromosomal rearrangement of a BDSF or STMST gene; 5) an alteration in the level of a messenger RNA transcript of a BDSF or STMST gene, 6) aberrant modification of a BDSF or STMST gene, such as ofthe methylation pattern of the genomic DNA, 7) the presence of a non- wild type splicing pattern of a messenger RNA transcript of a BDSF or STMST gene, 8) a non-wild type level of a BDSF or STMST-protein, 9) allelic loss of a BDSF or STMST gene, and 10) inappropriate
  • detection ofthe alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al (1988) Science 241:1077-1080; and Nakazawa et al (1994) PNAS 91 :360-364), the latter of which can be particularly useful for detecting point mutations in the BDSF or STMST-gene (see Abravaya et al. (1995) Nucleic Acids Res .23:675-682).
  • PCR polymerase chain reaction
  • LCR ligation chain reaction
  • This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mR ⁇ A or both) from the cells ofthe sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a BDSF or STMST gene under conditions such that hybridization and amplification ofthe BDSF or STMST-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size ofthe amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any ofthe techniques used for detecting mutations described herein.
  • nucleic acid e.g., genomic, mR ⁇ A or both
  • Alternative amplification methods include: self sustained sequence replication (Guatelli, J.C. et al, 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. et al, 1989, Proc. Natl. Acad. Sci. USA 86:1173- 1 177), Q-Beta Replicase (Lizardi, P.M. et all, 1988, Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection ofthe amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
  • mutations in a BDSF or STMST gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns.
  • sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
  • sequence specific ribozymes see, for example, U.S. Patent No. 5,498,531 can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
  • genetic mutations in BDSF can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin, M.T. et al. (1996) Human Mutation 7: 244-255; Kozal, M.J. et al. (1996) Nature Medicine 2: 753- 759).
  • a sample and control nucleic acids e.g., DNA or RNA
  • high density arrays containing hundreds or thousands of oligonucleotides probes e.g., DNA or RNA
  • genetic mutations in BDSF or STMST can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. et al. supra.
  • a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential ovelapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
  • any of a variety of sequencing reactions known in the art can be used to directly sequence the BDSF or STMST gene and detect mutations by comparing the sequence ofthe sample BDSF or STMST with the corresponding wild-type (control) sequence.
  • Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) PNAS 74:560) or Sanger ((1977) RN4S 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International
  • RNA/RNA or RNA/DNA heteroduplexes Other methods for detecting mutations in the BDSF or STMST gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242).
  • the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type BDSF or STMST sequence with potentially mutant RNA or DNA obtained from a tissue sample.
  • the double-stranded duplexes are treated with an agent which cleaves single-stranded regions ofthe duplex such as which will exist due to basepair mismatches between the control and sample strands.
  • RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1 nuclease to enzymatically digesting the mismatched regions.
  • either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion ofthe mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton et al. (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al. (1992) Methods Enzymol. 217:286-295.
  • control DNA or RNA can be labeled for detection.
  • the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in BDSF or STMST cDNAs obtained from samples of cells.
  • DNA mismatch repair enzymes proteins that recognize mismatched base pairs in double-stranded DNA
  • the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662).
  • a probe based on a BDSF sequence e.g., a wild-type BDSF or STMST sequence
  • a cDNA or other DNA product from a test cell(s).
  • the duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039.
  • alterations in electrophoretic mobility will be used to identify mutations in BDSF or STMST genes.
  • single strand conformation polymo ⁇ hism may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73-79).
  • Single-stranded DNA fragments of sample and control BDSF or STMST nucleic acids will be denatured and allowed to renature.
  • the secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change.
  • the DNA fragments may be labeled or detected with labeled probes.
  • the sensitivity ofthe assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence.
  • the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).
  • the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495).
  • DGGE denaturing gradient gel electrophoresis
  • DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR.
  • a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:12753).
  • oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad. Sci USA 86:6230).
  • Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
  • Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center ofthe molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11 :238).
  • amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189). In such cases, Hgation will occur only if there is a perfect match at the 3' end ofthe 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
  • the methods described herein may be performed, for example, by utilizing prepackaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a BDSF or STMST gene. Furthermore, any cell type or tissue in which BDSF is expressed may be utilized in the prognostic assays described herein.
  • BDSF or STMST protein e.g., modulation of angiogenesis or of an inflammatory response
  • agents e.g., drugs, compounds
  • an agent determined by a screening assay as described herein to increase BDSF or STMST gene expression, protein levels, or upregulate BDSF or STMST activity can be monitored in clinical trials of subjects exhibiting decreased BDSF or STMST gene expression, protein levels, or downregulated BDSF or STMST activity.
  • the effectiveness of an agent determined by a screening assay to decrease BDSF or STMST gene expression, protein levels, or downregulate BDSF or STMST activity can be monitored in clinical trials of subjects exhibiting increased BDSF or STMST gene expression, protein levels, or upregulated BDSF or STMST activity.
  • the expression or activity of a BDSF or STMST gene, and preferably, other genes that have been implicated in, for example, a proliferative disorder can be used as a "read out" or markers ofthe phenotype of a particular cell.
  • genes including BDSF or STMST, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates BDSF or STMST activity (e.g., identified in a screening assay as described herein) can be identified.
  • an agent e.g., compound, drug or small molecule
  • STMST activity e.g., identified in a screening assay as described herein
  • cells can be isolated and RNA prepared and analyzed for the levels of expression of BDSF or STMST and other genes implicated in the proliferative disorder, respectively.
  • the levels of gene expression can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one ofthe methods as described herein, or by measuring the levels of activity of BDSF or STMST or other genes.
  • the gene expression pattern can serve as a marker, indicative ofthe physiological response ofthe cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment ofthe individual with the agent.
  • the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration ofthe agent; (ii) detecting the level of expression of a BDSF or STMST protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post- administration samples from the subject; (iv) detecting the level of expression or activity ofthe BDSF or STMST protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity ofthe BDSF or STMST protein, mRNA, or genomic DNA in the pre-administration sample with the BDSF or STMST protein, mRNA, or genomic DNA in the post administration sample or samples; and (i) obtaining
  • increased administration ofthe agent may be desirable to increase the expression or activity of BDSF or STMST to higher levels than detected, i.e., to increase the effectiveness ofthe agent.
  • decreased administration ofthe agent may be desirable to decrease expression or activity of BDSF or STMST to lower levels than detected, i.e. to decrease the effectiveness ofthe agent.
  • BDSF expression or activity may be used as an indicator ofthe effectiveness of an agent, even in the absence of an observable phenotypic response.
  • the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant BDSF or STMST expression or activity.
  • treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.
  • “Pharmacogenomics”, as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market.
  • the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype”.)
  • a drug e.g., a patient's "drug response phenotype", or "drug response genotype”.
  • another aspect ofthe invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the BDSF or STMST molecules ofthe present invention or BDSF or STMST modulators according to that individual's drug response genotype.
  • Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.
  • the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant BDSF or STMST expression or activity, by administering to the subject a BDSF or STMST or an agent which modulates BDSF or STMST expression or at least one BDSF or STMST activity.
  • Subjects at risk for a disease which is caused or contributed to by aberrant BDSF or STMST expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
  • Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic ofthe BDSF or STMST aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
  • BDSF or STMST BDSF or STMST agonist or BDSF or STMST antagonist agent
  • BDSF or STMST agonist or BDSF or STMST antagonist agent can be used for treating the subject.
  • the appropriate agent can be determined based on screening assays described herein. The prophylactic methods ofthe present invention are further discussed in the following subsections.
  • the modulatory method ofthe invention involves contacting a cell with a BDSF or STMST or agent that modulates one or more ofthe activities of BDSF or STMST protein activity associated with the cell.
  • An agent that modulates BDSF or STMST protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a BDSF or STMST protein, a BDSF or STMST antibody, a BDSF or STMST agonist or antagonist, a peptidomimetic of a BDSF or STMST agonist or antagonist, or other small molecule.
  • the agent stimulates one or more BDSF or STMST activities. Examples of such stimulatory agents include active BDSF or STMST protein and a nucleic acid molecule encoding BDSF or STMST that has been introduced into the cell.
  • the agent inhibits one or more BDSF or STMST activites.
  • inhibitory agents include antisense BDSF or STMST nucleic acid molecules, anti- BDSF or STMST antibodies, and BDSF or STMST inhibitors.
  • These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g, by administering the agent to a subject).
  • the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a BDSF or STMST protein or nucleic acid molecule.
  • the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) BDSF or STMST expression or activity.
  • an agent e.g., an agent identified by a screening assay described herein
  • the method involves administering a BDSF or STMST protein or nucleic acid molecule as therapy to compensate for reduced or aberrant BDSF or STMSTexpression or activity.
  • Stimulation of BDSF activity is desirable in situations in which BDSF or STMST is abnormally downregulated and/or in which increased BDSF or STMST activity is likely to have a beneficial effect.
  • stimulation of BDSF or STMST activity is desirable in situations in which a BDSF or STMST is downregulated and/or in which increased BDSF or STMST activity is likely to have a beneficial effect.
  • inhibition of BDSF or STMST activity is desirable in situations in which BDSF or STMST is abnormally upregulated and/or in which decreased BDSF or STMST activity is likely to have a beneficial effect.
  • BDSF or STMST molecules ofthe present invention as well as agents, or modulators which have a stimulatory or inhibitory effect on BDSF or STMST activity (e.g., BDSF or STMST gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g, cancer) associated with aberrant BDSF or STMST activity.
  • pharmacogenomics i.e., the study ofthe relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration ofthe pharmacologically active drug.
  • a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a BDSF or STMST molecule or BDSF or STMST modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a BDSF or STMST molecule or BDSF or STMST modulator.
  • Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, M., Clin Exp Pharmacol Physiol, 1996, 23(10-11) :983- 985 and Linder, M.W., Clin Chem, 1997, 43(2):254-266.
  • two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymo ⁇ hisms.
  • G6PD glucose-6-phosphate dehydrogenase deficiency
  • oxidant drugs anti-malarials, sulfonamides, analgesics, nitrofurans
  • a genome-wide association relies primarily on a high-resolution map ofthe human genome consisting of already known gene-related markers (e.g. , a "bi- allelic” gene marker map which consists of 60,000-100,000 polymo ⁇ hic or variable sites on the human genome, each of which has two variants.)
  • gene-related markers e.g. , a "bi- allelic” gene marker map which consists of 60,000-100,000 polymo ⁇ hic or variable sites on the human genome, each of which has two variants.
  • Such a high-resolution genetic map can be compared to a map ofthe genome of each of a statistically significant number of patients taking part in a Phase II ll drug trial to identify markers associated with a particular observed drug response or side effect.
  • such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymo ⁇ hisms (SNPs) in the human genome.
  • SNP single nucleotide polymo ⁇ hisms
  • a "SNP" is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA.
  • a SNP may be involved in a disease process, however, the vast majority may not be disease- associated.
  • individuals Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome.
  • treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.
  • a method termed the "candidate gene approach” can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drugs target is known (e.g., a BDSF or STMST protein or a BDSF receptor of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version ofthe gene versus another is associated with a particular drug response.
  • the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action.
  • drug metabolizing enzymes e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19
  • NAT 2 N-acetyltransferase 2
  • CYP2D6 and CYP2C19 cytochrome P450 enzymes
  • the gene coding for CYP2D6 is highly polymo ⁇ hic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its C YP2D6-formed metabolite mo ⁇ hine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
  • a method termed the "gene expression profiling" can be utilized to identify genes that predict drug response.
  • a drug e.g., a BDSF or STMST molecule or BDSF or STMST modulator ofthe present invention
  • a drug e.g., a BDSF or STMST molecule or BDSF or STMST modulator ofthe present invention
  • Information generated from more than one ofthe above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a BDSF or STMST molecule or BDSF modulator, such as a modulator identified by one ofthe exemplary screening assays described herein.
  • novel genes exemplified herein were isolated utilizing a methodology which takes advantage ofthe fact that a majority of secreted and membrane-associated proteins posess at their amino termini a signal sequence, as defined herein.
  • the methodology identifies such secreted and/or membrane-associated proteins by virtue of their ability to direct export of a reporter protein, alkaline phosphatase (AP), from mammalian cells.
  • AP alkaline phosphatase
  • signal trapping or “signal sequence trapping” is described in detail in PCT/US97/20201 (WO98/22491 published May 28, 1998), the content of which is inco ⁇ orated herein in its entirety.
  • the present methodology is further combined with an improved method for cDNA library construction in which directional random promed cDNA libraries are prepared.
  • the invention is based, at least in part, on the discovery of a human gene encoding a novel brain-derived signaling factor protein, referred to herein as BDSF.
  • the methodology used to isolate the human BDSF-1 gene takes advantage ofthe fact that molecules such as BDSF-1 have an amino terminal signal sequence which directs certain secreted and membrane-bound proteins through the cellular secretory apparatus.
  • the human BDSF-1 mRNA was identified by screening of a human fetal brain cDNA library. This library was prepared using mRNA purchased from Clontech, Palo Alto (Cat. no, 6573-1). A signal trap cDNA library was prepared by ligating random primed double stranded cDNA into the expression vector, ptrAPl, resulting in fusions of cDNAs to the reporter, alkaline phosphatase (AP). DNAs from individual clones from this library were prepared by standard techniques and transfected into human embryonic kidney fibroblasts (293T cells). After 48 hours, cell supernatants were collected and assayed for AP activity.
  • AP alkaline phosphatase
  • Clones giving rise to detectable AP activity in the supernatants of transfected cells were analyzed further by DNA sequencing and the novel clones subjected to further DNA sequencing.
  • the nucleotide sequence encoding the human BDSF-1 protein is shown in Figure 1 and is set forth as SEQ ID NO: 1.
  • the full length protein encoded by this nucleic acid is comprised of about 244 amino acids and has the amino acid sequence shown in Figure 1 and set forth as SEQ ID NO:2.
  • the coding portion (open reading frame) of SEQ ID NO: 1 is set forth as SEQ ID NO:3.
  • human BDSF-1 protein includes a signal peptide (about amino acids 1-25 of SEQ ID NO:2), an Ig-like domain (about amino acids 41-129 of SEQ ID NO:2) and two conserved cysteine residues (about amino acids 48 and 127 of SEQ ID NO:2).
  • a clone, comprising the entire coding region of human BDSF-1 has been deposited with the American Type Culture Collection (ATCC), Manassas, Virginia, on May 15, 1998 and assigned Accession Number 98756.
  • the murine BDSF-1 gene was identified from a murine choroid plexus cDNA library. More specifically, a murine choroid plexus cDNA library was plated out and colonies picked into 96 well plates. The colonies were cultured, plasmids were prepared from each well, and several ofthe inserts were sequenced. The nucleotide sequences were compared against the human BDSF-1 nucleotide sequence. Upon review ofthe results from this sequence comparison, a murine BDSF-1 gene was obtained.
  • the nucleotide sequence encoding the murine BDSF-1 protein is shown in Figure 2 and is set forth as SEQ ID NO: 6.
  • the full length protein encoded by this nucleic acid is comprised of about 251 amino acids and has the amino acid sequence shown in Figure 2 and set forth as SEQ ID NO:7.
  • the coding portion (open reading frame) of SEQ ID NO:6 is set forth as SEQ ID NO:8.
  • Notable features ofthe murine BDSF-1 protein include a signal peptide (about amino acids 1-24 of SEQ ID NO:7), an Ig-like domain (about amino acids 40-128 of SEQ ID NO:7) and two conserved cysteine residues (about amino acids 47 and 126 of SEQ ID NO:7).
  • human BDSF The expression of human BDSF was analyzed using Northern blot hybridization and a probe specific for human BDSF.
  • the DNA was radioactively labeled with 32p. dCTP using the Prime-it-kit (Stratagene, La Jolla, CA) according to the instructions of the supplier.
  • Filters containing human mRNA Multi-Tissue Northern I, Multi-Tissue Northern II and Multi-Tissue Northern III from Clontech, Palo Alto, CA
  • Filters containing human mRNA Multi-Tissue Northern I, Multi-Tissue Northern II and Multi-Tissue Northern III from Clontech, Palo Alto, CA
  • filters containing human brain mRNA (Brain-Subregion Blot from Clontech) were also probed for human BDSF-1 expression.
  • results of Northern blot hybridization indicate that human BDSF is expressed as an approximately 5.0 kilobase transcript in all tissues (spleen, lymph node, thymus, peripheral blood leukocytes, bone marrow, stomach, thyroid, spinal cord, trachea, adrenal, testis, small intestine, heart, placenta, lung, liver, kidney and pancreas).
  • BDSF mRNA expression was also observed in human fetal liver.
  • BDSF is expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in E. coli and the fusion polypeptide isolated and characterized.
  • GST glutathione-S-transferase
  • human or murine BDSF is fused to GST and this fusion polypeptide is expressed in E. coli, e.g., strain PEB199.
  • Expression ofthe GST-BDSF fusion protein in PEB199 is induced with IPTG.
  • the recombinant fusion polypeptide is purified from crude bacterial lysates ofthe induced PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis ofthe polypeptide purified from the bacterial lysates, the molecular weight ofthe resultant fusion polypeptide is determined.
  • the pcDNA/Amp vector by Invitrogen Co ⁇ oration (San Diego, CA) is used.
  • This vector contains an SV40 origin of replication, an ampicillin resistance gene, an E. coli replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site.
  • a DNA fragment encoding the entire BDSF protein and a HA tag (Wilson et al (1984) Cell 37:767) fused in-frame to its 3' end ofthe fragment is cloned into the polylinker region ofthe vector, thereby placing the expression ofthe recombinant protein under the control ofthe CMV promoter.
  • the BDSF DNA sequence is amplified by PCR using two primers.
  • the 5' primer contains the restriction site of interest followed by approximately twenty nucleotides ofthe BDSF coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag and the last 20 nucleotides ofthe BDSF coding sequence.
  • the PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA).
  • the two restriction sites chosen are different so that the BDSF gene is inserted in the correct orientation.
  • the Hgation mixture is transformed into E. coli cells (strains HB101, DH5a, SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence ofthe correct fragment.
  • COS cells are subsequently transfected with the BDSF-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAE- dextran-mediated transfection, lipofection, or electroporation.
  • Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
  • the expression ofthe BDSF protein is detected by radiolabelling ( 35 S-methionine or 35 S-cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988) using an HA specific monoclonal antibody. Briefly, the cells are labeled for 8 hours with 35 S-methionine (or 35 S-cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated proteins are then analyzed by SDS-PAGE.
  • 35 S-methionine or 35 S-cysteine available from NEN, Boston, MA, can be used
  • DNA containing the BDSF coding sequence is cloned directly into the polylinker ofthe pCDNA Amp vector using the appropriate restriction sites.
  • the resulting plasmid is transfected into COS cells in the manner described above, and the expression ofthe BDSF protein is detected by radiolabelling and immunoprecipitation using a BDSF specific monoclonal antibody
  • BDSF BDSF
  • MSCVneo retroviral vector
  • MSCVneo The entire open reading frame of BDSF is subcloned into the retroviral vector MSCVneo, described in Hawley et al. (1994) Gene Therapy 1 :136-138.
  • Cells (293Ebna, Invitrogen) are then transiently transfected with the BDSF construct and with constructs containing viral regulatory elements, to produce high titre retrovirus containing the BDSF gene.
  • the virus is then used to transfect mice. These mice are then tested for any gross pathology and for changes in biological response, e.g., cell proliferation and/or differentiation, using standard assays.
  • Example 5 Chromosomal Location of BDSF Human BDSF maps to hu7pl2-14 between markers WI-967 and WI-4253 close to the CMT2D (Charcot-Marie-Tooth neuropathy) locus.
  • the syntenic chromosome in mouse, mol 1 is in close meansimity with the mouse known genes: egfr (epidermal growth factor receptor), ddc (dopa decarboxylase) and cob l(cordondian)).
  • BDSF also mapped close to the following human genes: ADCYAP1R1 (adenylate cyclase activating polypeptide 1), AMPH (amphiphysin), BLVRA (biliverdin reductase A), OGDH
  • oxoglutarate dehydrogenase OCM (oncomodulin)
  • EGFR epidermal growth factor receptor
  • Example 6 In situ Expression of BDSF Mouse tissues were analysed in situ for expression of BDSF. The in situ data (a
  • the 'signal sequence trapping' method described above was utilized to analyse the sequences of several cDNAs of a cDNA library derived from bronchial epithelial cells which had been stimulated with the cytokine, TNF ⁇ .
  • This analysis identified a partial human clone having an insert of approximately 231 kb containing a protein- encoding sequence of approximately 225 nucleotides capable of encoding approximately 75 amino acids of STMST (e.g., the start met through residue 74 of, for example, SEQ ID NO: 15).
  • This cDNA was used to re-screen the library. Two full-length cDNA clones were isolated. Sequencing of these clones revealed the nucleotide sequences of human STMST-1 and STMST-2.
  • the nucleotide sequence encoding the human STMST-1 protein is shown in Figure 4 and is set forth as SEQ ID NO: 14.
  • the full length protein encoded by this nucleic acid is comprised of about 297 amino acids and has the amino acid sequence shown in Figure 4 and set forth as SEQ ID NO: 15.
  • the coding portion (open reading frame) of SEQ ID NO: 14 is set forth as SEQ ID NO: 16.
  • the nucleotide sequence encoding the human STMST-2 protein is shown in Figure 5 and is set forth as SEQ ID NO: 17.
  • the full length protein encoded by this nucleic acid is comprised of about 609 amino acids and has the amino acid sequence shown in Figure 5 and set forth as SEQ ID NO: 18.
  • the coding portion (open reading frame) of SEQ ID NO: 17 is set forth as SEQ ID NO: 19.
  • the amino acid sequence of STMST-1 diverges from that of STMST-2 at about amino acid residue 263 of SEQ ID NO: 15 or SEQ ID NO: 18.
  • the amino acid sequence of STMST-1 lacks the extensive cytoplasmic domain of STMST-2.
  • a BLAST search (Altschul et al (1990) J. Mol. Biol. 215:403) ofthe nucleotide sequence of human STMST-2 has revealed that STMST-2 is significantly similar to a protein identified as protein A-2 (human A-2, Accession No. U47928; murine A-2, Acession No. AC002393) which were sequenced as part ofthe sequencing of human chromosome 12pl3 and mouse chromosome 6, respectively.
  • the human A-2 protein appears to be one of a family of alternatively-spliced gene products which further includes protein A-l (Acession No. U47925) as well as A-3 (Acession No. U47929).
  • the A-2 proteins like the STMST proteins ofthe present invention, include many features indicative ofthe G protein-coupled receptor family of proteins.
  • the STMSTs ofthe present invention contain conserved cysteines found in the first 2 extracellular loops (prior to the third and fifth transmembrane domains) of most GPCRs (cys 83 and cys 161 of SEQ ID NO:15 or SEQ ID NO: 18).
  • a highly conserved asparagine residue in the first transmembrane domain is present (asn25 in SEQ ID NO:15 or SEQ ID NO:18).
  • Transmembrane domain two ofthe STMST proteins contains a highly conserved leucine (leu49 of SEQ ID NO: 15 or SEQ ID NO: 18). The two cysteine residues are believed to form a disulfide bond that stabilizes the functional protein structure.
  • a highly conserved tryptophan and proline in the fourth transmembrane domain ofthe STMST proteins is present (tipl35 and pro 145 of SEQ ID NO: 15 or SEQ ID NO: 18).
  • the third cytoplasmic loop contains 49 amino acid residues and is thus the longest cytoplasmic loop ofthe three, characteristic of G protein coupled receptors.
  • a highly conserved proline in the sixth transmembrane domain is present (pro260 of SEQ ID NO: 15 and SEQ ID NO: 18).
  • the proline residues in the fourth, fifth, sixth, and seventh transmembrane domains are thought to introduce kinks in the alpha-helices and may be important in the formation ofthe ligand binding pocket.
  • the conserved (in the second cytoplasmic loop) HRM motif found in almost all Rhodopsin family GPCRs is present in the STMST proteins ofthe instant invention (hisl 07, argl 08, metl 09 of SEQ ID NO: 15 or SEQ ID NO: 18).
  • the arginine ofthe HRM sequence is thought to be the most important amino acid in GPCRs and is invariant).
  • an almost invariant proline is present in the seventh transmembrane domain of STMST-2 (pro294 of SEQ ID NO: 18).
  • the STMST family of proteins like the A-2 family of proteins, are refered to herein as G protein-coupled receptor-like proteins.
  • STMST-1 is also predicted to contain the following sites: cAMP and cGMP-dependent protein kinase phosphorylation site at aa 225-228 (KRRS); Protein kinase C phosphorylation sites at aa 153-155 (SER) and at aa 290-292 (SSR); Casein kinase II phosphorylation sites at aa 228-231 (SSID) and at aa 291-294 (SRQD); N- myristoylation sites at aa 9-14 (GSAVGW), aa 169-174 (GLGFGV), aa 181-186 (GGSVAM), aa 187-192 (GVICTA), aa 232-237 (GSEPAK), and at aa 244-249 (GLVTTI); Amidation site at aa 223-226 (QGKR).
  • KRRS Protein kinase C phosphorylation sites at aa 153-155
  • SSR Casein kinase II
  • STMST is predicted to contain the following sites: cAMP- and cGMP-dependent protein kinase phosphorylation sites at aa 225-228 (KRRS), aa 393-396 (RRFS), aa 436-439 (RRAS), and at aa 453-456 (RRRS); Protein kinase C phosphorylation sites at aa 253-255 (SER), aa 268-270 (SLR), aa 392-394 (TRR), aa 462-464 (SLR), aa 482-484 (SPR), and at aa 560-562 (SLR); Casein kinase II phosphorylation sites at aa 228-231 (SSID), aa 324-327 (SDDE), aa 328-331 (TSLE), aa 364-367 (SALE), aa 396-399 (SHDD), aa 417-420 (SGED), aa 466-469 (SALD), aa 506-509
  • Tissue Distribution of STMST-1 mRNA This Example describes the tissue distribution of STMST mRNA, as determined by Northern blot hybridization.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur de nouveaux polypeptides, de nouvelles protéines et molécules d'acides nucléique, tous étant sécrétés et associés à une membrane (telles que des molécules BDSF et STMST). Outre les protéines isolées, pleine longueur, l'invention porte également sur des protéines de fusion isolées, des peptides antigéniques et des anticorps. L'invention porte notamment sur des molécules d'acide nucléique, des vecteurs d'expression de recombinaison contenant une molécule d'acide nucléique de l'invention, des cellules hôtes dans lesquelles ont été introduits les vecteurs d'expression, et des animaux transgéniques dans lesquels un gène BDSF ou STMST été introduit ou dissocié. Des procédés de diagnostic, criblage et thérapeutiques utilisant les compositions de cette invention sont également décrits.
PCT/US1999/011842 1998-05-29 1999-05-28 Nouvelles proteines secretees et associees a une membrane et leurs utilisations WO1999061463A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41015/99A AU4101599A (en) 1998-05-29 1999-05-28 Novel secreted and membrane-associated proteins and uses therefor
CA002328902A CA2328902A1 (fr) 1998-05-29 1999-05-28 Nouvelles proteines secretees et associees a une membrane et leurs utilisations
JP2000550867A JP2002516079A (ja) 1998-05-29 1999-05-28 新規分泌型および膜会合型タンパク質ならびにそのための用途
EP99924537A EP1082335A4 (fr) 1998-05-29 1999-05-28 Nouvelles proteines secretees et associees a une membrane et leurs utilisations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8712198A 1998-05-29 1998-05-29
US8689298A 1998-05-29 1998-05-29
US09/087,121 1998-05-29
US09/086,892 1998-05-29

Publications (1)

Publication Number Publication Date
WO1999061463A1 true WO1999061463A1 (fr) 1999-12-02

Family

ID=26775272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011842 WO1999061463A1 (fr) 1998-05-29 1999-05-28 Nouvelles proteines secretees et associees a une membrane et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1082335A4 (fr)
JP (1) JP2002516079A (fr)
AU (1) AU4101599A (fr)
CA (1) CA2328902A1 (fr)
WO (1) WO1999061463A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048189A1 (fr) * 1999-12-28 2001-07-05 Helix Research Institute Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
GB2367823A (en) * 2000-07-24 2002-04-17 Smithkline Beecham Corp AXOR28 polypeptides and polynucleotides
WO2001083523A3 (fr) * 2000-04-28 2002-06-13 Millennium Pharm Inc Nouvelles proteines et molecules d'acide nucleique stmst et utilisations correspondantes
EP1255771A4 (fr) * 2000-02-14 2004-09-29 Smithkline Beecham Corp Nouveaux composes
EP2143796A3 (fr) * 2000-02-29 2010-03-17 Millennium Pharmaceuticals, Inc. Récepteurs couplés à la protéine G 1983, 52881, 2398, 45449, 50289, et 52872, et leurs utilisations
US7998485B2 (en) 2006-05-11 2011-08-16 Universiteit Gent Sialoadhesin-related compositions and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BONALDO FATIMA DE M., LENNON G., SOARES M. B.: "NORMALIZATION AND SUBTRACTION: TWO APPROACHES TO FACILITATE GENE DISCOVERY.", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 06., no. 09., 1 September 1996 (1996-09-01), US, pages 791 - 806., XP002039972, ISSN: 1088-9051 *
CROSS S. H., ET AL.: "PURIFICATION OF CPG ISLANDS USING A METHYLATED DNA BINDING COLUMN.", NATURE GENETICS., NATURE PUBLISHING GROUP, NEW YORK, US, vol. 06., no. 03., 1 March 1994 (1994-03-01), NEW YORK, US, pages 236 - 244., XP000578157, ISSN: 1061-4036, DOI: 10.1038/ng0394-236 *
See also references of EP1082335A4 *
WILSON R., ET AL.: "2.2 MB OF CONTIGUOUS NUCLEOTIDE SEQUENCE FROM CHROMOSOME III OF C. ELEGANS.", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 368., no. 6466., 3 March 1994 (1994-03-03), United Kingdom, pages 32 - 38., XP002029739, ISSN: 0028-0836, DOI: 10.1038/368032a0 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048189A1 (fr) * 1999-12-28 2001-07-05 Helix Research Institute Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
EP1255771A4 (fr) * 2000-02-14 2004-09-29 Smithkline Beecham Corp Nouveaux composes
EP2143796A3 (fr) * 2000-02-29 2010-03-17 Millennium Pharmaceuticals, Inc. Récepteurs couplés à la protéine G 1983, 52881, 2398, 45449, 50289, et 52872, et leurs utilisations
WO2001083523A3 (fr) * 2000-04-28 2002-06-13 Millennium Pharm Inc Nouvelles proteines et molecules d'acide nucleique stmst et utilisations correspondantes
GB2367823A (en) * 2000-07-24 2002-04-17 Smithkline Beecham Corp AXOR28 polypeptides and polynucleotides
US7998485B2 (en) 2006-05-11 2011-08-16 Universiteit Gent Sialoadhesin-related compositions and methods

Also Published As

Publication number Publication date
CA2328902A1 (fr) 1999-12-02
EP1082335A4 (fr) 2003-03-05
EP1082335A1 (fr) 2001-03-14
JP2002516079A (ja) 2002-06-04
AU4101599A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
WO2000029577A9 (fr) Nouveaux elements de la famille de proteines receptrices de capsicine/vanilloide, et utilisations de ceux-ci
EP1017813A1 (fr) Nouvelles molecules de la super-famille des recepteurs de tnf et utilisations de ces molecules
US8133689B2 (en) Members of the capsaicin/vanilloid receptor family of proteins and uses thereof
US20020099197A1 (en) Novel potassium channel molecules and uses therefor
US6197551B1 (en) Spoil-1 protein and nucleic acid molecules and uses therefor
US20020045209A1 (en) Novel potassium channel molecules and uses therefor
WO1999061463A1 (fr) Nouvelles proteines secretees et associees a une membrane et leurs utilisations
EP1071749A1 (fr) Molecules d'acide nucleique et de proteine lrsg et leurs utilisations
US7517659B2 (en) Potassium channel molecules and uses therefor
WO2002038767A2 (fr) Nouvelles proteine recepteur couplee a une proteine g et molecules d'acides nucleiques, et utilisations associees
US20030087343A1 (en) Novel SLGP nucleic acid molecules and uses therefor
WO1999037818A1 (fr) Nouvelles molecules de la superfamille du recepteur du facteur de necrose tumorale et leurs utilisations
WO2001083523A2 (fr) Nouvelles proteines et molecules d'acide nucleique stmst et utilisations correspondantes
EP1792913A1 (fr) Nouvelles protéines secretées et associées à la membrane et leur utilization
US20020055474A1 (en) Novel molecules of the tnf ligand superfamily and uses therefor
US20020086982A1 (en) Novel EBI-3-ALT protein and nucleic acid molecules and uses therefor
WO2000017236A2 (fr) Proteines reliees a l'apoptose et utilisations associees
WO2002002602A2 (fr) Nouvelle proteine slgp et nouvelles molecules d'acide nucleique et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 41015/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 550867

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2328902

Country of ref document: CA

Ref country code: CA

Ref document number: 2328902

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999924537

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999924537

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1999924537

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999924537

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载